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Abstract 
Telomerase is an important housekeeping enzyme which plays a critical role in cell 
survival. It is expressed in high levels in proliferative cells but is down-regulated in 
somatic cells, which makes it a potentially important tumor marker. However, the 
histochemical detection of telomerase is highly difficult and to-date, few antibodies to the 
enzyme have been reported to be able to detect the enzyme inside the nucleus of cells. The 
primary aim of my study was to produce a good monoclonal antibody to locate the enzyme 
in cells. 
Since I had no previous experience working with telomerase or with monoclonal 
antibodies, to familiarize myself in these areas, I began my study by working with a 
previously-produced anti-telomerase antibody called mAb 476. This antibody was 
produced in our laboratory against the N-terminal segment of the catalytic subunit 
(N-TERT) of human telomerase. This antibody was able to stain the TERT antigen in the 
nucleus of human cells including that from tumor tissues. However, this staining required 
the use of a special antigen retrieval buffer called Enhancing buffer. This suggested that 
either the enzyme was buried inside the nuclear scaffold or the site in the enzyme to which 
mAb 476 binds was blocked by some factors or accessory proteins of the enzyme. Another 
unusual and interesting finding about the hybridoma 476 cells was the fact that although 
they could grow well in tissue culture, they perished when introduced to the mouse 
peritoneum. This was presumed to be due to the presence of IL-6 in the peritoneum, which 
up-regulated the antibody synthesis in cells, hence increasing the amount of 
immune-complexes formed inside the cell between the antibody and the enzyme. These 
immune-complexes were transported to the cell nucleus which became toxic to the cell. 
Thus, my initial study was to help in a complex study to see whether spleen cells producing 
anti-telomerase antibodies in mice could be killed by injecting IL-6 to the telomerase 
antigen-immunized mice. This issue was totally new and such kind of experiments had not 
been done before. I thus developed a FACS method to enumerate the anti-N-TERT 
antibody-producing cells in mouse spleen, which could be used to monitor the population 
change in antibody-producing cells following IL-6 treatment. However, due to time 
limitation, I had not continued with the intended study. 
In my main study, I produced an antibody to the C-terminal end of TERT (C-TERT), 
following the same method used for the production of mAb 476. The purpose was to find 
out whether this antibody would behave in the same way as mAb 476. Thus, I 
characterized this anti-C-TERT antibody, called mAb A63, using various immunoassays, 
including ELISA, Western blotting and immunohistochemical staining. mAb A63 was 
found to bind to the nucleus of the HL-60 cells but only when the Enhancing buffer was 
used, just like mAb 476. This suggests that the whole catalytic subunit of telomerase is 
buried inside the nucleus, not just the N-terminal end. The antibody was also able to stain 
tumor cells in liver cancer tissues, although not as well as mAb 476. However, unlike 
hybridoma 476，hybridoma A63 cells were able to grow in the mouse peritoneum and 
formed ascites. The reason for this is probably because mAb A63 was found to be 
un-reactive with mouse TERT, and is thus not a true auto-antibody in mouse cells (unlike 
mAb 476). 
Thus, my study is useful and informative in that it confirms the hidden location of 
telomerase in cells, and it also helps to understand the mechanism of suicide in certain 






































於mAb A63不能辨認小鼠的端粒酶催化亞單位，這一現象很可能是因爲mAb A63並不 
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Antigens are substances that are recognized by antibodies. Most antigens are immunogens 
that can trigger an immune response in a person or an animal thus prompting the 
production of antibodies by the immune system. However, some antigens, such as haptens 
and short peptides which are of low molecular weight, are not immunogenic. Antigens are 
usually proteins or polysaccharides in nature, which can be part of bacterial cells, viruses 
or other types of microorganisms. Lipids and nucleic acids can be immunogenic when 
combined with proteins or polysaccharides. Besides, glycoproteins from transplanted 
tissues or organs, such as those occurring as components on the surface of transfused blood 
cells, are highly immunogenic and antigenic, and are the common cause of transplantation 
rejection problems. 
1.1.2 Types of antigen 
Antigens can be generally grouped as either extrinsic or endogenous. 
a) Extrinsic antigens are antigens that come from outside of the body, from a wide range of 
sources including foods, allerogenic particles in the air, and various kinds of pathogens, e.g. 
bacteria and viruses that can invade into our body. Plant seeds, pollens, fungi, bacteria, and 
animal hair are common examples of extrinsic antigens. These antigens can enter the body 
and contact with the immune system by inhalation, ingestion or injection. They are then 
taken into antigen-presenting cells (APCs) by endocytosis or phagocytosis and processed 
into fragments. APCs present the fragmented antigen peptide through MHC class II 
molecules to T-helper cells that are CD4 positive through the T cell receptor, and the T 
cells thus activated, secrete specific types of cytokines. Cytokines are important substances 
that activate various cells of the immune system, such as cytotoxic T cells (CTLs), 
antibody secreting B cells, macrophages. 
B) Endogenous antigens are antigens that are generated inside the cell. They can be the 
product of normal metabolism of the cell involving host constituents and these are called 
autoantigens, or are derived from viral and intracellular bacterial infection. These antigens 
are then fragmented and presented to T cells through MHC class 1 molecules. In the 
process of normal immune system development, negative selection ensures the deletion of 
CTLs that are self-reactive. 
1.1.3 Autoantigens 
Autoantigens or self-antigens are a special type of endogenous antigens recognized by a 
person's own immune system when the person develops autoimmunity or an autoimmune 
disease. These antigens can be simple or complex proteins found in the cell cytoplasm or 
nucleus, or on the cell surface, or sometimes, exist as DNA or RNA epitopes. Some of the 
well known autoantigens associated with autoimmune diseases are summarized in Table 
1.1. 
Table 1.1 Some common autoantigens associated with autoimmune disease (adapted from 
Peter &Shoenfeld，1996) 
Auto-antigen Disease condition 
double-stranded-DNA Systemic lupus erythematosus (SLE) -
Exosome complex Scleromyositis 
Ro or La Systemic lupus erythematosus (SLE) and neonatal heart 
block, primary Sjogren's syndrome 
Smith Systemic lupus erythematosus (SLE) 
phospholipid Antiphospholipid syndrome 
smooth muscle Chronic autoimmune hepatitis 
mitochondria Primary biliary cirrhosis 
nicotinic acetylcholine receptor Myasthenia gravis 
voltage-gated calcium channel Lambert-Eaton syndrome 








neutrophil perinuclear (p-ANCA) Microscopic polyangiitis, Churg-Strauss syndrome, 
Systemic vasculitides (non-specific) 
IgG (Rheumatoid factor) Rheumatoid arthritis 
neutrophil perinuclear (pANCA) Polyarteritis nodosa 
centromere CREST syndrome 
Autoantigens become immunogenic as a consequence of the loss of immune tolerance. In 
the normal state, the immune tolerance system ensures our immune system does not react 
to self-antigens (Burnet, 1968; reviewed in Sinclair, 2004). However, this mechanism can 
be lost by the effect of environmental or genetic factors. This loss leads to autoimmunity 
which may or may not result in autoimmune disease. 
Autoimmunity can be either systemic or local, depending on the autoantigen localization 
and biological function. The mechanisms for generating autoimmunity are various, include 
the following (Pollard, 2006) 
1) T-Cell Bypass — Activation of B cells requires the help of T cells in a normal situation. 
However, this requirement can be bypassed, if a person is infected by organisms which 
produce super-antigens, that can trigger polyclonal activation of B-cells, or, which bind 
directly to the p-subunit of T-cell receptors in a non-specific fashion. Once B cells are 
activated abnormally, autoantibodies will be produced in large amounts. 
2) Molecular Mimicry — Extrinsic antigens are generally different from host antigens, but 
these antigens may share structural similarities with host antigens in particular regions. 
Thus, antibodies produced against an extrinsic antigen, which mimics a self-antigen, can 
also bind to the particular host antigen, and be able to produce large amounts of 
autoantibodies. The most well-known form of molecular mimicry is observed in Group A 
beta-haemolytic streptococci, which shares conformational antigens with human 
myocardium, and the cross-reactive autoantibodies thus cause cardiac manifestations of 
rheumatic fever. 
3) Idiotype Cross-Reaction - Idiotypes (id) are antigenic epitopes found in the Fab 
I 
fragments of the immunoglobulin molecule. Following infection by some viruses, 
antibodies are produced to the viruses which later induce anti-id antibodies. These anti-id 
antibodies crossreact with the host-cell receptor which resembles an internal part of the 
virus. 
4) Cytokine Dysregulation - Cytokines regulate the immune system response involving 
both B and T cell development and activation. If the cytokine level is somehow 
dysregulated to become abnormally high or low, self-reactive B or T lymphocytes can be 
inadvertently activated. 
5) Dendritic cell apoptosis -Dendritic cells, are potent antigen-presenting cells that can 
activate T-lymphocytes. A defect in dendritic cell apoptosis can lead to inappropriate 
systemic lymphocyte activation, and the subsequent loss of immune tolerance. 
6) Epitope spreading or epitope drift - The immune system somehow targets not only the 
primary epitope but also other epitopes in the antigen-antibody complex. In contrast to 
molecular mimicry, the other epitopes targetted need not be structurally similar to the 
primary epitope. 
Autoimmune disorder may result from the malfunctioning of immune system germline 
genes, particularly those relating to the T cell receptor and the immunoglobulins. Besides, 
certain MHC class II allotypes are also found to correlate with several autoimmune 
diseases. For example, HLA DR2 is strongly positively correlated with systemic lupus 
erythematosus (SLE) (Steven et al. 2005) and multiple sclerosis (Zipp et al. 2000) and 
negatively correlated with diabetes mellitus Type I (Type I DM) (Awdeh et al. 2006). 
1.1.4 Telomerase is an important autoantigen 
Telomerase is a housekeeping enzyme of cells and is thus an important autoantigen. It is a 
ribonucleoprotein enzyme and a specialized RNA-dependent, DNA polymerase. It is an 
important enzyme in maintaining the telomere length in chromosomes, which plays a 
critical role in cell division and the aging process. 
The telomere has several essential biological functions. Besides protecting chromosomes 
from end-to-end fusion (Blackburn 2000)，it also provides a way for the replication of 
chromosomes, and serves as a molecular clock to control the replicative capacity of the 
cells including their senescence. Because conventional DNA polymerase cannot fully 
replicate the 3' end of the lagging strands of linear DNA molecules, telomeric DNA will get 
progressively lost from the ends of chromosome at each cell division cycle. This 
progressive telomere shortening was shown to provide a signal for entry of cells into a state 
of senescence. This function of telomere in replicating cells acts as a molecular clock and 
maintenance of functional telomeres at chromosome ends is very important in cell cycle. In 
most eukaryotes, the replenishment of telomere DNA is performed by the telomerase 
function as a ribonucleoprotein reverse transcriptase. The replicative potential of 
mammalian cells and telomere length correlates with the telomerase functions. 
Telomerase has been studied in a variety of organisms since its first discovery in 
tetmhymena thermophila, and later in human beings. Importantly, in humans, telomerase 
has been found to be over-expressed in more than 90% of tumor cells, in immortalized cell 
lines and in germ line cells. On the other hand, it is often down-regulated in somatic cells. 
Human telomerase is composed of two different parts, one is the nucleic acid that serves as 
the template for telomere elongation, and the other is the protein catalytic subunit that 
performs the polymerase function. 
Telomere 
The telomere is a structure highly conserved in eukaryotic organisms with chromosomes. 
Being a large nucleoprotein complex located at the ends of chromosomes, it builds up a 
protective mechanism for preventing chromosomal ends from undergoing degradation and 
ligation with other chromosomes. This protective mechanism is very important to 
chromosomal genetics. Without telomeric caps, chromosomes will undergo end-to-end 
fusions and form abnormal dicentric or multicentric chromosomes, which usually leads to 
serious problems in cell mitosis. 
Mammalian telomere is usually composed of telomeric DNA and several kind of proteins, 
which act together to form a distinct telomere structure. Telomeric DNA has numbers of 
G-rich tandem repeats. For mammalian cells, the repeat is TTAGGG, which will be added 
to form a length of 10-15kb in humans at each chromosomal end by the functional enzyme 
(de Lange et al. 1990)，telomerase. The telomere has a single-strand 3' overhanging of 
100-200 bases which is the substrate for telomerase to perform telomeric elongation, by 
recognizing and hybridizing to a complementary sequence (Wright et al. 1997). However, 
the end of G-rich telomeric single strands can also fold up to form higher-order structure, 
so called "T-loop"，which can inhibit telomerase activity (Parkinson et al. 2002; Zahler et 
al. 1991; Griffith et al. 1999). 
The protein factors populating the telomere, like TRFl, TRF2, Potl, play different but 
important roles in regulating the telomere length and capping (Blackburn., 2001; de-Lange 
2002; Broccoli et al. 1997; van-Steensel et al. 1997). There are also other proteins 
associating with telomere to form a telomeric-DNA complex, including TIN2, TANKl, 
TANK2, MRE11,RAD50, NBSl and Ku complex (Goytisolo and Blasco 2002; Blackburn 
2000; Blackburn 2001; de-Lange 2002). 
LL4b Telomerase enzyme 
As introduced before, telomerase is a kind of ribonucleoprotein enzyme. It is a specialized 
RNA-dependent, DNA polymerase that maintains the telomeric DNA length at the 
chromosome ends. The reverse transcriptase function comes from two essential subunits, 
the telomerase RNA component (TERC), and the telomerase catalytic component (TERT) 
(Hahn 2003). Besides, there are also several associated proteins, including TEPl，p23, 
Hsp90 and 14-3-3proteins (Harrington et al. 1997; Forsythe et al. 2001). The diagram of 
TERT and TERC can be seen in Figure 1.1. 
In 1985, it was proposed that telomerase contained at least one essential component 
responsible for the catalytic addition of nucleotides (Greider et al, 1985). Then, this 
catalytic subunit of telomerase was purified from Euplotes addiculatus and Tetrahymenaa 
thermophila as pi23，with a size of about 123-125kD and sequence analysis found that 
pi23 had very close amino acid homology to reverse transcriptase (Lingner and Cech 1996; 
Lingner et al. 1997). Another protein identified and isolated from yeast that was essential 
for telomere maintenance, Est2p, was found to be similar to the pi23 protein and contains 
the hallmarks of reverse transcriptase (Lendvay et al. 1996). Based on sequences of Est2p 
and pi23，TERT cDNAs were identified from different species. It was found that TERT 
contains 7 motifs that are highly conserved among reverse transcriptase from retroviruses 
and retroponsons (Nakamura et al. 1997; Nakamura and Cech 1998; Eickbush 1997). 
The highly conserved 7 motifs of TERT protein plays essential role for the function of 
telomerase in DNA polymerization using RNA as template. TERT also contains a 
telomerase specific motif (T motif) that is involved in the association between TERT and 
TERC. The diagram of hTERT diagram showing the structure of 7 motifs can be seen in 
Figure 1.2. Deletion or mutation of the T motif can markedly reduce the telomerase activity 
(Nakamura et al. 1997; Weinrich et al. 1997; Bryan et al. 2000). Associated proteins Hsp90 
and p23 are necessary for telomerase activity and for efficient telomerase assembly (Holt et 
al. 1999; Forsythe et al. 2001). A 14-3-3 protein binds to TERT and regulates the nuclear 
localization of telomerase (Seimiya et al. 2000). 
The telomerase RNA component, TERC, serves as a sequence template for telomere 
elongation. TERC contains a sequence complementary to the cognate telomeric DNA 
sequence, TTAGGG (Greider and Blackburn 1989; Shippen-lentz and Blackburn 1990). In 
humans, this 11-nucleotide sequence, 5’-CUAACCCUAAC，specifies synthesis of the 
telomeric DNA sequence (Feng et al. 1995). Phylogenic analysis of the telomerase RNAs 
from different species reveals the conservation of secondary structure which may be 
essential for telomerase activity because it involves in binding to TERT (Romero and 
Blackburn 1991; Bhattacharyya and Blackburn 1994; Chen et al. 2000). Disruption of the 
interaction between TERT and TERC can disrupt telomerase activity (Keppler and Jarstfer 
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2004). 
The telomerase's primary function is repeated copying of the telomerase RNA template 
into new telomeric DNA. Studies on human telomerase activity showed that human TERT 
(hTERT) and human TERC (hTERC) are the minimal components for telomerase function 
(Tesmer et al. 1999; Mitchell and Collins 2000; Bachand and Autexier 2001). In the 
elongation process, TERC provides the RNA template for complementary sequence to be 
added to the telomere ends and TERT provides the active site for the catalysis. Besides, 
telomerase also has important function in capping of the telomere, the failure of which can 
trigger the cell into senescence or apoptosis (Karlseder et al. 1999). Thus, there is poor 
elongation telomerase activity when long telomeres are present (Marcand et al. 1999; 
reviewed by Chan, 2002). 
The unique property of telomerase that it is highly expressed in human tumor cells but not 
in normal cells (Kim et al. 1994) offers a good opportunity to target these cells for 
anti-cancer therapy. Inhibiting this enzyme activity either by TERT or TERC inhibition is 
novel to cancer therapy. Examples are the use of antisense oligodeoxynucleotides (ODN) 
(Herbert et al. 1999) that are complementary to hTERC, and a dominant-negative TERT 
gene construct (Zhang et al. 1999; Hahn et al. 1999)，both of which were able to efficiently 
reduce the telomerase activity thus inhibiting tumor cell or immortal cell line growth. 
However, there will be a lagging effect before the telomere reaches the lengths critical for 
triggering proliferation inhibition or apoptosis when the telomerase is inhibited. Some 
cancer cells might not be affected by this form of inhibition (Kondo et al. 1998) or they can 
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develop telomerase-independent mechanisms (Bryan et al. 1997). 
1.2 Antibodies 
1.2.1 Preamble 
Antibodies, also known as immunoglobulins (Ig), are proteins produced by the immune 
system under the stimulation of antigens. They can be found in the blood and other body 
fluids of vertebrates and function by identifying and neutralizing foreign substances, like 
bacteria and virus. Each kind of antibody can recognize a specific kind of antigen. The 
specific functions of immunoglobulins are due to the structure of their active sites. 
Antibodies are produced by immune cells called B cells, which are named after the bursa of 
Fabricius, a specific organ in birds where avian B cells become mature and in which B cells 
were first defined in birds in the 1960s (Glick 1977). It was discovered later that 
mammalian B cells development occurs in the bone marrow and spleen. 
1.2.2 Ig structure 
Immunoglobulins are composed of several subunits. The basic feature is a tetramer 
structure including two identical light chains of about 25 kDa and two heavy chains of 
about 50-75 kDa, linked by disulfide bonds (Figure 1.3). The C-terminals of both the heavy 
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and light chains form the constant region, which is different for different isotypes of 
antibodies. The N-terminal segments of the chains, known as the variable region, are 
highly variable among Igs and play the specific function in recognizing specific antigens. 
The constant region of the heavy chain is responsible for various immunological functions 
such activation of complement, interaction with effector cells, transport of Igs and 
compartmentalization of Igs. The constant region of the heavy chain has three or four 
homology regions of about 110 amino acids long each. 
In the variable region of both light and heavy chains, there are three clusters called the 
hyper variable or complementarity-determining region (CDR). There are also four 
framework regions (FR) outside the CDRs, which are more conserved sequences than 
CDRs and involved in maintaining the three-dimensional structure of the variable regions. 
The hinge region located between CH! and CH2 of the alpha, beta and gamma heavy chains. 
Due to the particular structure, hinge regions are very sensitive to proteolytic enzymes. The 
IgG molecule can thus be digested by pepsin into two Fab fragments each having single 
antigen binding site and one Fc region that do not have antigen binding activity. Hinge 
regions play an important role in the Ig function, by allowing the Fab fragment to be 
flexible and bind to the antigen in different locations (Roitt 2001; Paul 1999). IgM and IgE 
antibodies lack the hinge region. 
1.2.3 Ig synthesis 
The light and heavy chains of immunoglobulins are synthesized separately by different 
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parts of the membrane bound polyribosome. After synthesis, the light chain quickly 
associates with the heavy chain by the formation of disulfide bonds, in the cistemae of the 
smooth endoplasmic reticulum (ER). The synthesis of the light chain and heavy chain 
polypeptides and their assembly into Ig molecules takes place within 10 minutes and the 
secretion of newly synthesized Igs takes about 30 minutes (Scharff and Laskov 1970; 
Bevan et al. 1972; Litman and Good 1978). The secretion of the antibodies follows the 
common secretion pathway of secreting proteins. During the intracellular transport, there is 
an orderly addition of carbohydrate residues. The presence of the attached carbohydrate 
plays an important role in Ig structure and function (Lund et al. 1990; Muraoka and 
Shulman 1989). 
Through gene rearrangement of 3 separate germline genes encoding the heavy chain and 
types of light chain, millions of antibodies for different antigens can be produced in a 
person or an animal (Hozumi and Tonegawa, 2004). The antigenic site recognized by an 
antibody is called an epitope. A particular antigen may have several different epitopes or 
repeated epitopes. An epitope can be sequential or conformational, depending on the 
whether it is formed by adjacent amino acids sequences or amino acids from separate 
portions but juxtaposed by folding. Conformational antigens are more common because 
antibodies are usually cross-reactive (Pier et al. 2004). The antibody binding site located in 
the Fab of the heavy and light chain is formed mainly by the six CDRs. The shapes of the 
binding sites depend on the particular antigens, and are often highly complementary in 
both conformation and charge to the antigens. The links between an antigen epitope and the 
antibody-binding site can be salt links, hydrogen bonds and van der Waals interactions. 
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The linkage varies among antigen-antibody complexes. 
1.2.4 Immunoglobulin isotypes 
Antibodies can be classified according to their genetic variations and structure differences. 
As mentioned before, the immunoglobulin structure unit is composed of a pair of light 
chains and heavy chains. Light chains have 2 different types, K and \ representing 2 
different light chain gene segments. Two light chains of an individual antibody are 
identical. There are five different types of heavy chains named by Greek letters: y, 5, a, \i 
and 8, by which antibody isotype or antibody class is defined. The different 5 antibodies 
class is then named as IgG，IgD, IgA, IgM and IgE, respectively. Different classes of 
antibodies differ from one another not only by the type of heavy chain present, but also by 
their overall structure, the specific biological function, specific location, and how they deal 
with the specific antigen (Litman and Good, 1978). 
Different antibody isotypes are produced during the process of B cell development and 
antibody production by plasma cells. Naive B cells, which are immature and have never 
been exposed to any antigen previously, can only produce membrane bound IgM 
antibodies. Co-expression of IgD antibodies with the IgM antibodies on the membrane 
happens when B cells become mature and ready for antigen contact. After engagement 
with the appropiate antigen through the membrane receptor, B cells become activated. 
Activated B cells divide and differentiate into antibody-producing cells called plasma cells, 
which secrete soluble forms of the antibodies (Roitt, 2001). 
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IgM antibodies have a pentamer structure formed by covalent linked disulfide bond, and 
have a molecular weight higher than 900 kDa. Because the chain gene is positioned first 
in the chromosomal segment in which all the heavy chain genes located, IgM is the first 
immunogloblin class to be expressed by B cells. It is also the first type of antibodies 
produced by the fetus. IgM functions in the early stages of humoral immunity and these 
molecules cannot diffuse through the cell membrane or the human placenta. However, its 
high avidity resulting from its polymeric structure makes it particularly effective in 
complement activation. The presence of infectious-specific IgM antibodies in a patient 
serum indicates a recent infection in diagnosis of infectious diseases (Decker et al. 1981; 
Wielaard et al. 1988). 
IgG antibodies belong to 4 subclasses: IgGl，IgG2, IgG3, IgG4. IgG antibodes are the most 
abundant (75%) of the serum immunogloblins in humans. They are found in both blood 
and tissue fluids, and predominate in the secondary antibody response. Maternal IgG 
antibodies absorbed through the placenta support the humoral immunity of infants before 
their own immune system develops. IgG can bind to various kinds of pathogens including 
bacteria, virus and fungi, and also trigger complement activation and antibody-dependent 
cell-mediated cytotoxicity (ADCC) (Poston and Morgan 1983). This IgG-triggered ADCC 
can also be used in cancer therapy (Ralph and Nakoinz 1984). 
IgA plays an important role in the mucosal immunity and is produced predominantly in 
mucosal linings and found in mucous secretions, including tear, saliva, intestinal juice, 
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colostrum and vaginal fluid. IgA can survive in harsh environment of respiratory and 
digestive tract due to its resistance to degradative enzymes. It can provide protection 
against microbes in body secretions and IgA present in milk also provide maternal 
antibody protection for infants (Vierucci et al. 1967). 
IgD is a monomeric antibody with a less defined function, but is found on the membrane of 
non-activated mature B cells (Kim et al. 1992). 
IgE plays a crucial role in allergy and is the least abundant antibody class in serum. It also 
plays an important role in the immune defence mechanism against parasitic worms and 
protozoan parasites. IgE triggers powerful immune reactions by activating mast cells when 
bound with the corresponding antigen. Binding of the antigen-bound IgE molecule to the 
FceRI receptor on mast cells triggers the degranulation of and the subsequent release of 
mediators from mast cells. IgE can also cross-link with basophils to release IL-4，IL-13 
and other types of inflamatory mediators (Turner and Kinet 1999). 
1.2.5 Monoclonal antibodies (mAb) 
Monoclonal antibodies are produced by antibody-producing cells all derived from a single 
parental cell. Monoclonal antibodies are thus mono-specific. In theory, it is possible to 
produce monoclonal antibodies against any given substance. They can be used to detect, 
locate or purify the particular antigen. The high specificity of monoclonal antibodies 
makes them important tools that can be used in studies of biochemistry, molecular biology 
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and medicine (Schook 1987) 
In the 1970s, immortalized B cell myelomas were discovered, and it was found that these 
cancerous cells produced a single type of antibody (Periman 1970). In 1975, the Noble 
prize-winning discovery made by Georges Kohler and Cesar Milstein described the 
technique for producing monoclonal antibodies from hybridoma cells. The key of this 
technique is to use a myeloma cell line, which is immortal, and does not produce any 
antibody, and fuse this with a functional B cell that produce antibodies to a given antigen 
but which lacks immortality. If the fusion process is successful, fused cells can be selected 
that produce the desired antibodies. 
Nowadays, production of mouse monoclonal antibodies is highly successful. Because a 
mouse can be immunized with the desired antigen at will, it is possible to construct 
hybridoma cells that produce monoclonal antibodies against any antigen as desired. 
Polyethylene glycol (PEG) is used to fuse the myeloma B cells with the splenocytes. A 
selective medium is used which allows only the fused cells, called hybridomas, to grow. 
This takes advantage of the fact that myeloma cells have lost the ability to synthesize 
hypoxanthine-guanine-phosphoribosyl transferase (HGPRT).This enzyme allows cells to 
synthesize purines from extra-cellular sources ofhypoxanthine as the precursor. Normally, 
the absence of HGPRT will not cause problems because cells have an alternative 
biochemical pathway that they can use to synthesize purines. However, when cells are 
exposed to aminopterin (a folic acid analogue), they are unable to use this rescue pathway 
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and are fully dependent on HGPRT for survival. The selective culture medium is called 
HAT medium because it contains hypoxanthine, aminopterin，and thymidine. Hybridoma 
cells are able to grow indefinitely in HAT medium because the spleen cell partner supplies 
HGPRT while the myeloma partner is immortal (Springer, 1985; Kobayashi et al. 1994). 
The diagram of producing a hybridoma is shown in Figure 1.4. 
Successful fusion leads to the production of a mixture ofhybridomas. This mixture of cells 
is then purified by limiting dilution and clones grown from single parent cells producing 
the desired monoclonal antibodies can be selected. 
Production of monoclonal antibodies can be enriched by several methods because the 
antibody level in the culture medium for culturing hybridomas is usually low. When the 
hybridoma cells are injected to mice in the peritoneal cavity, they produce tumors 
containing an antibody-rich fluid called ascites fluid. Ascites fluid contains 
milligram-levels of the desired monoclonal antibody. Purification of the monoclonal 
antibody can be achieved by using normal antibody purification methods. Protein-A and 
Protein G columns are normally used to isolate IgG antibodies. 
Once monoclonal antibodies for a given antigen have been produced, they can be used to 
detect the antigen in a Western blotting test, an ELISA or an immunofluorescence test. 
The antibodies can also be labeled or coupled to several biochemical or fluorescence 
markers for complex tests such as inhibition assays or sandwich methods that capture the 
desired antigen. They are also very useful in immunohistochemistry which detects the 
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antigen in fixed tissue sections. 
Monoclonal antibodies are also very useful for treating diseases. Treatment of cancer using 
monoclonal antibodies is becoming an exciting possibility because of their high specificity. 
One possible treatment for cancer involves monoclonal antibodies that bind only to cancer 
cell-specific antigens and which are labeled with a toxin or radioisotope to kill the target 
cell (Koppel 1990). 
1.2.6 Autoantibodies 
Autoantibodies are antibodies specific for autoantigens. They are usually produced by the 
immune system of patients suffering from autoimmune diseases. Normally, the immune 
system avoids making antibodies to the body's own cells. However, sometimes the 
immune system goes astray and fails to recognize one's own cells as self, leading to the 
production of autoantibodies, e.g. anti-nuclear antibodies (Peter and Shoenfeld，1996). The 
cause of this abnormal production of autoantibodies can be varied and is not well 
understood, which can be genetic or environmental in nature, or both. Many autoantibodies 
are diagnostic of autoimmune diseases. Examples for autoimmune diseases are coeliac 
disease, diabetes mellitus type 1 (IDDM)，systemic lupus erythematosus (SLE), Sjogren's 
syndrome, Churg-Strauss syndrome, multiple sclerosis (MS), Hashimoto's thyroiditis, 
Graves丨 disease, idiopathic thrombocytopenic purpura, and rheumatoid arthritis (RA). The 
corresponding autoantigens for these diseases are found in Table 1.1. Figure 1.5 shows 3 
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different autoantibodies to different autoantigens located in different compartments inside 
the Hep-2 cells. 
However, low levels of autoantibodies can sometimes be found in normal people, which 
are not sufficient to cause an autoimmune disorder. These low level autoantibodies may in 
fact be beneficial rather than pathologic. For example, such low-level auto-reactive 
antibodies to MHC molecules may help to control CD4 T cell responses (Via et al. 1996). 
The pathogenic autoantibodies may cause harm or disease in various ways. The most 
common way is the direct dysfunction or injury caused by the autoantibodies themselves. 
For example, autoantibodies against red blood cell antigens can cause red blood cells to 
lyse thus leading to hemolytic anemia (Caulfield et al. 1989). Autoantibodies against 
certain types of hormones can down-regulate the hormonal level to cause disease (Fares et 
al. 2001; Gonzalez et al. 2001). Autoantibodies to various kinds of enzymes can also cause 
cellular dysfunction, while those that target cell membrane receptors cause either abnormal 
stimulatory or inhibitory cellular function (Awdeh et al. 2006). 
Besides circulating freely in the blood, autoantibodies can bind directly to the basement 
membrane of the kidney in glomerulonephritis or localize in the intercellular components 
of the skin in pemphigus and bullous pemphigoid. Autoantibodies can also bind to their 
antigens in the blood to form immune complexes, and these complexes can either cause an 
allergic effect or induce local organ dysfunction. 
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1.2.7 Telomerase detection and antibodies to telomerase 
Telomerase is an enzyme that is normally down-regulated in somatic cells but highly active 
in dividing cells such as germ cells or in those that are malignant (Greider 1998; Shay and 
Bacchetti 1997). As described previously, telomerase can thus be a potential tumor marker 
or target, especially the catalytic TERT subunit. Thus, scientists have performed many 
experiments to measure the TERT enzymic activity in cancer tissues and several methods 
have been developed to detect the enzyme. -
Measuring the enzymic activity in cancer tissue extracts by a PCR-based assay (TRAP; 
Kim et al. 1994) was first used. This method was widely used but the weakness with it is 
the fact that it is expensive and imprecise. Another method introduced was to use an 
anti-sense probe to localize the telomerase mRNA, by the method called in situ 
hybridization. This method is more accurate at the single cell level. However, the method 
was developed initially to detect the RNA subunit of telomerase (Feng et al. 1995)，which 
several studies have shown not to be accurate in representing the enzyme function (Ulaner 
et al. 2000). After the catalytic subunit of human TERT was discovered (Nakamura et al. 
1997), this was found to be more conservative and more representative of telomerase 
activity. In situ hybridization (ISH) experiments using TERT as probe showed that the 
telomerase enzyme was highly active in several types of tumor cells (Falchetti et al. 2000; 
Kolquist et al. 1998; Nakamura et al. 1998; Wada et al. 2000). 
Another way of detecting TERT in cells for telomerase enzyme activity is to use antibodies 
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against the TERT subunit. However, very few monoclonal antibodies for TERT have been 
developed to-date and most studies were performed using polyclonal antibodies or 
antiserum (Tahara et al. 1999; Kawakami et al. 2000; Wada et al. 2000; Frost et al. 2000). 
Because telomerase is present in low abundance in cells (Frost et al. 2000; Wada et al. 
1998)，the immuno-histochemical detection of telomerase has been extremely difficult and 
many previous detections investigators have found it necessary to use some form of signal 
amplification in order to detect the enzyme (Wada et al. 2000; Tahara et al. 1999). 
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1.3 Object and Scope of Study 
My study was based on the production of an anti-telomerase monoclonal antibody. 
Previous work in our laboratory had produced and characterized an anti-telomerase 
antibody recognizing the N-terminal sequence ofhTERT (N-TERT), called mAb 476. This 
antibody was able to stain the TERT antigen in the cell nucleus but only with the 
requirement of an antigen-retrieving buffer, the Enhancing buffer, which is quite different 
from many other nuclear antigens that we know. Based on this unusual of feature of mAb 
476，I planned to produce another telomerase antibody that would recognize hTERT from 
the C-terminal side (C-TERT) and characterize this new telomerase antibody. Besides, the 
hybridoma cells that produce mAb 476 also behaved differently to other 
antibody-producing hybridoma cells. It appeared that the 476 cells could not survive in the 
peritoneum of primed mice to form ascites because of the presence of a cytokine, IL-6. 
Studies performed by my colleagues previously showed that this special feature was due to 
the autoreactivity of mAb 476 to mouse TERT. 
Since I had no experience in working with either monoclonal antibodies or 
antibody-producing cells, I performed a preliminary study using mAb 476 and its 
hybridoma, to establish a new technique to detect N-TERT specific antibody-producing 
cells from Balb/c mice immunized with the N-TERT antigen. This technique was used to 
count the number of autoreactive cells in mice, with the intention to study the effect IL-6 
treatment on these animals. 
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After being familiar with the techniques involving monoclonal antibodies and hybridoma 
cells, I started the main part of my study which was to construct a hybridoma to produce an 
anti-C-TERT antibody following the same method used for the production of mAb 476， 
and to characterize this antibody using several immunoassays, including the 
immunohistochemical staining of TERT in human cancerous cells, HL-60, or other cell 
types, under normal staining condition or using the Enhancing buffer. Besides, the 
hybridoma produced would also be injected into the primed mouse peritoneum, to check 
whether these C-TERT specific antibody-producing cells would survive in the presence of 
IL-6. 
This study is thus the following questions regarding telomerase: Is the C-terminal of TERT 
also inaccessible to antibody probes? If so, what is the reason for the requirement of the 
Enhancing buffer in the immunostaining of TERT? What is the reason for the failure of 
hybridoma 476 to survive? Is the antibody produced to C-TERT also autoreactive? The 
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Figure 1.1 Diagram of telomerase function and telomerase accessory proteins, showing 
the TERT and TERC components, the latter recognizing the chromosomal repeats through 
its complementary sequence (A), and various accessory proteins that play regulatory 
functions (B) (Goytisolo and Balsco 2002). 
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Figure 1.2 Structure of human telomerase reverse transcriptase (hTERT)，showing the 7 
motifs and a N-terminal T2 motif (adapted from Li and Liu 2002). 
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Figurel.3 Immunoglobulin structure. This graph shows the different regions of the 
immunoglobulin molecule consisting of two heavy chains (in red and blue color) and two 
light chains (in green and yellow color). The single region, the two Fab regions, the hinge 












Figure 1.4 Diagram showing how hybridoma is produced, details are described in 1.2.5. 
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• 
Figure 1.5 Autoantibodies to guanosine staining the nucleolus and cytoplasm of Hep-2 
cells (40x, immunofluorescence, own unpublished data). 
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Chapter Two 
Materials and Methods 
2.1 Materials 
2.1.1 Animals 
The mouse strain used for production of monoclonal antibodies is Balb/c, which is 
obtained from Laboratory Animal Unit, The Chinese University of Hong Kong. During the 
experiment interval, all the mice are maintained and bred in the animal house of Prince of 
Wales Hospital, The Chinese University of Hong Kong. 
2.1.2 Antibodies 
Mab2 is an IgGl antibody of the phosphorylcholine (PC)-binding MOPC 511 family and 
was purified from culture supernatant by protein G affinity chromatography (Sigma, 
St.Louis, MO). 
Secondary antibodies used in ELISA，Western blot, immuno-histochemical staining and 
flow cytometry were obtained from commercial sources. HRP-conjugated goat-anti-mouse 
Ig (all classes), FITC-conjugated goat-anti-mouse Ig (all classes), 
anti-Mouse-anti-CD 19-PE streptavadin-HRP and streptavadin-FITC antibodies were 
bought from BD Pharmingen (San Diego, CA, US). 
2.1.3 Primers 
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Human TERT DNA fragment, corresponding to the GenBank accession number AfO 15950 
clone, was generated from the mRNA of HL-60 cells by RT-PCR (Leung et al. 2000). 
N-TERT DNA fragment, corresponding to nucleotide (nt) 1682-2039 (378 bp) was 
generated using primers: 5' -AAG GGA TCC AAG TTC CTG CAC TGG CTG ATG-3', 
and 5'-AAG GGA TCC CTC GTA GTT GAG CAC GCT GAA-3,，both containing a 
restriction site for BamH I. C-TERT DNA fragment, corresponding to nucleotide (nt) 
2552-2861 (309 bp) was generated using primers: BTUppl 5' -CGT GGA TCC CAG 
GGC TCC ATC CTC TCC ACG-3', and BTLow2 5，-CG ATG AAT TCC CAC CTC 
CAG GGT CCG GGT ATC -3，，containing restriction site for BamH I and EcoR I， 
respectively. Primers were synthesized by Invitrogen (Carlsbad, CA). 
2.1.4 Culture media and reagents 
RPMI-1640 supplemented with glutamine, non-essential amino acids and sodium pyruvate 
was purchased from Sigma (St.Louis, MO, US). Fetal calf serum (FCS)，streptomycin and 
penicillin were obtained from Gibco (Grand Island, NY, US). Bacto-tryptone and 
bacto-yeast extracts were obtained from Sigma. HAT supplement 5Ox containing lOmM 
sodium hypoxanhine, 1.6mM thymidine and 40uM aminopterin, as well as HT medium 
(lOOx) containing lOmM sodium hypoxanthine and 1.6mM thymidine were obtained from 
GibcoBRL (Gaithersburg, MD, US). Polyethylene glycol (PEG; Mol. Wt. 4000) was 
obtained from Sigma. 
2.1.5 Chemicals and enzymes 
Taq DNA polymerase was purchased from Perkin-Elmer Cetus (Boston, MA, US). dNTPs 
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was obtained from Amersham (Piscataway, NJ，US). Restriction enzymes and T4 ligase, 
were purchased from New England Biolab (Bevely, MA). DNase I and DNA nucleic acid 
markers were obtained from Invitrogen (Carlsbad, CA). 
Enzymes and reagents used in protein work, including Nonidet P-40 (NP-40), protease 
inhibitor cocktail (lOOx), affinity column of protein-G sepharose and saponin, were 
obtained from Sigma (St.Louis, MO). Phenylmethylsulfonyl Fluoride (PMSF), lysozyme 
and proteinase K were purchased from BioRad Laboratories (Hercules, CA). Prestained 
BenchMark protein ladder was bought from Invitrogen (Carlsbad, CA). 
2.1.6 Miscellaneous chemicals 
Other chemicals used in the experiments were bought from Sigma, Merck or Invitrogen. 
2.1.7 Commercial kits 
Various commercial kits were used in different experiments including: DNA miniprep kit 
(Qiagen Inc.，Gmbh，Hilden); BCA protein assay kit (Pierce, Rockford, IL); Qiaquick gel 
extraction kit (Qiagen Inc., Gmbh, Hilden); Lumingen ™ PS-3 detection reagent (ECL) 
(Amersham, Buckinghamshire, HP79NA); DNA sequencing kit (Appled Biosystem, 
Foster City, CA). 
2.1.8 Instruments 
The following equipment was used in my study: Thermal cyclers (Model: PTC-200 and 
PTC-220, MJ Reserach, Inc, South San Francisco, CA). Semi-Dry Transfer cell and Gene 
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Pulser (BioRad Laboratories, Hercules, CA). Auto sequencer (Model: ABI-310, Applied 
Biosystems, Provindence, RI). Flow cytometry (Model: FACS Calibur，Becton Dickinson, 
Franklin Lakes, NJ). ELISA reader, Ultro Microplate Reader (Bio-Tek Instruments Inc 
Winooskik, VT). 
2.1.9 Buffers 
Enhancing Buffer: obtained from IDL Biotech, Bromma, Sweden 
NP-40 lysis buffer: 1% Nonidet P-40 (v/v), 150 mM NaCl, 50mM Tris，pH 7.6， 
Ix Protease inhibitor cocktail, 100 j^g/ml phenylmethylsulfonyl fluoride (PMSF) 
Proteinase-K digestion buffer: lOOmM Tris-Cl (pH 7.6)，200mM NaCl, 0.2% SDS, 
5mM EDTA and 100 |Lig/ml Proteinase K 
Saponin permeable buffer: PBS buffer containing 2% FCS and 1% saponin 
DAB: 20^1 DAB stock (2.5% 3.3'-Diaminobenziden Tetrahydrochloride in TBS, pH7.6) in 
1ml TBS (pH7.6) with 1 30% H2O2 
Bicarbonate buffer: 50mM Sodium Bicarbonate (NaHCOs) buffer, pH 9.6 
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2.2 Methods 
2.2.1 Cells and cell culture 
Hybridoma A63 was produced by fusion between NSO cells and spleen cells of Balb/c 
mice that were immunized with a recombinant C-Terminal TERT antigen following 
established methods (Wun et al. 2000; Leung et al. 2000; Lim et al. 1996)，and is described 
in 2.2.6 and chapter four. 
Hybridoma 476 produces an IgGl antibody specific to recombinant N-terminal TERT 
antigen (Leung et al. 2005). Details and some further characterization were described in 
chapter three. 
Hybridoma Mab2 is an IgGl antibody producing hybridoma that is specific to 
phosphorylcholine (Lim et al. 1994; Poon et al. 2002; Ortega-Pierres et al. 1996). 
NSO cell was the fusion myeloma partner used for making hybridoma A63. SP2/0 cells 
were used in the production of hybridoma 476. 
HL-60 cells are human acute promyelocytic leukemia cells that were used as natural 
telomerase source in immunohistochemical staining. 
NSO, Sp2/0 and HL-60 cell lines were obtained from American Type Culture Collection 
(Manassas, NA). All the cell lines were maintained in RPMI-1640 culture medium 
supplemented with 10% fetal calf serum (FCS) and lOOU/ml penicillin/streptomycin. Cell 
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growth was maintained by humidified incubator at 37°C, with 5% CO2. 
2.2.2 Polymerase chain reaction (PGR) 
Ix PGR buffer II, 2mM MgCb, 0.2mM dNTPs, lU Tag polymerase, 5pmol corresponding 
specific 5' and 3' primer each, and 0.5ul sample DNA, were mixed with ddHsO to a total 
volume of 25ul. 
PGR conditions were as follows: lOmin at 95 °C for activation of the enzyme, followed by 
25-35 cycles of Imin 9 4 I m i n 55°C-60°C and Imin 7 2 a n d at last 72 for lOmins. 
PGR products obtained were analyzed by running in 1% gel with ethidium bromide. With 
comparing to +50kb DNA ladder, size of expected gene fragment was estimated for correct 
amplification. After confirmation, the products were purified by Qiaquick gel Extraction 
kit and kept at-20 
2.2.3 Cloning of C-terminal gene fragment to pGEX cloning vector 
PGR products amplified from C-terminal telomerase gene were digested by restriction 
enzyme Bam H I and EcoR I，purified by cutting out from 1% gel and then purified by 
Qiaquick gel extraction kit. After that, this gene segment was ligated with pGEX cloning 
vector at 16 °C overnight, which was pretreated by the same restriction enzyme. The 
ligated vectors were then transformed into BL21 competent Escherichia coli (E.coli) cells 
by electroporation. 2ul of ligated plasmid was used for lOOul competent cells and loaded in 
to an electrical pulsing cuvette (for 1ml medium), and the pulsing condition was set at 2k 
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volts, 200 Q and 25 uF. The electric shocked bacteria with plasmid transfected were mixed 
with 1ml Luria-Bertani (LB) medium as soon as possible and applied to a recover growth 
for 45 minutes, 37 °C, with shaking at 250rpm.After overnight incubation, the positive 
clones containing the expected vector will be selected by forming colonies on 
ampicillin-containing LB medium plate. 
The plasmid DNA containing expected gene fragments for sequencing was prepared using 
DNA miniprep kit (Qiagen) following the manufacturer's instruction and then was 
sequenced using DNA sequencing kit (Applied Biosystems) with corresponding 
sequencing primer, lul of plasmid DNA was digested by restriction enzyme EcoRI and 
BamHI and amplified by primer BTUppl and BTLow2 using PGR. The amplified DNA 
sequence was purified and mixed with BigDye Terminators to perform sequencing cycle. 
After that, the product was purified by ethanol precipitation and analyzed by the Applied 
Biosystems DNA Analyzer. The DNA sequence ofTERT amplified in the PGR reaction 
was confirmed by Genebank (http:www.ncbi.nlm.nih.gov). 
2.2.4 Detection of antibody activity by ELISA 
Recombinant C-TERT or N-TERT antigen was diluted in bicarbonate buffer (pH9.6)，and 
then coated to 96-well Immunon II microtitier plate (Dynatech Lab., Alexandria, VA, USA) 
overnight at 4 °C. Dilution of antigen coated was determined by a serial dilution 
experiment, and the usual dilution used is from 500 fold to 4000 fold, depending on the 
antigen stock concentrations. The coated plate was first blocked by lOOul 2.5% BSA 
diluted in PBS (w/v) for 1 hour at 37 After a wash of the plate with PBS-T, standard 
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samples (diluted purified monoclonal antibody, ascites fluid, serum or culture supernatant) 
with different dilutions in blocking solution (2.5% BSA/PBS) in a total lOOul volume were 
added and incubated for an interval time (depending on the specific experiment, 1 hour to 
4 hours) at 37 °C. A second wash was then applied to the plate using PBS-T for 3 times 
repeats. After that, secondary antibody, goat anti-mouse Igs conjugated with horseradish 
perioxidase (HRP) diluted with blocking buffer 1000-fold was added and incubated for 1 
hour at 37 °C. After the second three washes with PBS-T, the reaction was then developed 
with TMB for 10-15 minutes at room temperature. The reaction was stopped by lOOul of 
0.18M H2SO4, and the absorbance was measured at 450nm by ELISA reader, with a 
reference optimal density (OD) at 630nm. 
2.2.5 Histochemicai Staining 
2.2.5.1 Preparation of paraffin-embedded formalin-fixed sections 
NSO and HL-60 cells were allowed to grow into large number in RPMI-1640 medium and 
then harvested and washed with PBS. Cell number was calculated by trypan blue exclusion. 
Around 2 million cells were harvested and washed with ice-cold PBS twice, and then fixed 
with 10% Phosphate-buffered formalin (pH 7.0) at 4°C overnight. The fixed cells were 
then mixed with 1% agar (prepared previously, melt to liquid and cooled to about 60 °C 
when use). The mixture was pelleted by centrifugation at 10，000g for Imin and quickly 
cooled by incubation with ice. Pelleted cells were further fixed for another half hour and 
used for dehydration. The dehydrated cells were embedded by paraffin and then used for 
preparation of 4 urn sections. The sections cut were mounted on the glass slides 
(SuperFrost), produced by Mental-Glaser (Braunschweig, Germany).The slides were 
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heated at 55 °C in oven overnight to fix the sections well onto them. 
2.2.5.2 Detection of telomerase using anti-telomerase antibody 
The sections prepared was first de-waxed by incubation in xylene twice (5 minutes each) 
and re-hydrated by incubation in absolute alcohol twice (5 minutes each), 5mins incubation 
in 95% alcohol once, and 5mins incubation in 70% alcohol once. For other samples like 
human HCC samples and placenta sections, blocking of endogenous peroxidase activity 
was required by incubation with 0.03% H2O2 for 30mins. After briefly washing in ddHzO， 
the sections were then blocked by a blocking buffer, which was 1% BSA in TBS. If 
enhancing buffer was used, the blocking buffer was 1% BSA in enhancing buffer 
After blocking, sections are applied to primary antibody (either labeled with biotin or not) 
diluted in blocking buffer 10-50 fold (depending on antibody activity against antigen, for 
purified monoclonal antibody, it could be 100-fold dilution or even more diluted). Primary 
antibody incubation time is different for different kinds of antibodies. For mAb 476 and 
mAb A63，it took 1-4 hours to visualize a significant staining, while for ascites fluid or 
biotin-labeled samples, 0.5-1 hour was enough. The incubation was performed at room 
temperature. After being washed three times in TBS within 10 minutes, the sections were 
then incubated with secondary antibody, either anti-mouse Igs-HRP or streptavidin-HRP, 
diluted 1: 250 in 1% BSA/TBS (normal buffer) at room temperature for 1 hour. After 
second washing for three times using TBS (3-4 minutes) each, the sections were developed 
with substrate solution of DAB for 10-15 minutes, with observation of appearance of 
staining signals under light microscope. Then the sections were counterstained by 
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hematoxylin and eosin. 
At last, sections were dehydrated by 5 minutes incubation in 95% alcohol once and twice in 
absolute alcohol for 5 minutes each. After cleared in xylene for 5mins incubation twice, the 
sections were mounted with DPX and photograph can be taken. 
2.2.6 Hybridoma production 
2.2.6.1 Spleen cell preparation 
Balb/c mice immunized with recombinant N-TERT antigen were sacrificed. The spleen 
was taken out aseptically and crushed into single-cell suspension using a fme-mesh screen 
in a petri dish, which was filled with 10ml serum-free RPMI-1640 medium. Cell 
suspension was prepared by gentle squeezing the spleen organ against the mesh screen 
with a rubber-tipped syringe plunger. A pipetting up-and-down motion was performed to 
make cells separate and suspended in the medium. After washing by RPMI medium using 
centrifugation at 1200 rpm for 10 minutes, the cells were tapped loose and the red blood 
cells were lyzed by 3ml 0.85% NH4CI for 3 minutes. FCS was then loaded to the cells and 
the white blood cells were pelleted at 1200rpm for 5 minutes and re-suspended in 4 ml 
serum-free RPMI-1640 medium. The cell concentration was determined by a 
haemocytometer. 
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2.2.6.2 Cell fusion and hybridoma selection 
The fusion cell line NSO, is a mouse myeloma cell line, which is a subclone of NS-1 
(P3/NSl/l-Ag4-l ECACC No. 85011427) without Ig secreting or light chain-synthesising 
flinction.The cells are resistant to lO i^M azaguanine，and die in the presence of HAT 
medium. These cells were harvested at log phase when cultured, and resuspended at 1 xlO^ 
cells /ml in serum-free RPMI-1640 medium and kept at 37 °C before use. 20 million spleen 
cells from immunized Balb/c mice were mixed with 50 milllion NSO cells. The cells were 
washed with PBS and then the cell mixture was pelleted at 1000 rpm for 5 minutes. After 
removing most of the supernatant, the cells were tapped loose in the centrifuge tube and 
warmed by 3 7 � C water. 1ml of polyethylene glycol (PEG) solution (50% PEG, 10% 
DMSO) in PBS was added to the cell mixture dropwise with constant gentle rolling of the 
tube. It was essential to keep the cells warm by keeping the bottom of the centrifuge tube, 
where the cell pellet located, warmed in the hand. The loading of PEG was required to be 
finished in 1.5 minutes and later gradually diluted by 10 ml of RPMI 1640 medium with 
10% FCS within 2 minutes. The diluted mixture was then centrifuged at 700rpm (low 
speed to prevent cells sticking together) for 5 minutes. After that, the cells were 
resuspended in 40 ml of RPMI-1640 medium with 10% FCS containing 1 xlO^ feeder cells 
derived from the spleen cells from a non-immunized normal Balb/c mouse prepared by the 
same method in 2.2.6.1. lOOul of the aliquots of the mixture was pipetted into each well of 
four 96-well plates. 
80ul of the culture supernatant was removed from each well and changed into 100 ul of 
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selective HAT medium (RPMI-1640 medium, with 10% FBS, containing O.lmM Sodium 
hypoxanthine, 0.016mM thymidine, 0.4uM aminopterin, 5ug/ml gentamycin, lOOU/ml 
penicillin, lOOug/ml streptomycin. For every 4 days, 80ul of spent culture supernatant was 
removed and replaced with fresh HAT medium. On day 14, the HAT medium was replaced 
with HT medium (same components as HAT but without anminopterin). After 10-14 days, 
clones of fused cells were visible by microscope. The spent culture supernatant was used in 
ELISA as to be described in 2.2.7 and the positive clones were kept for limiting dilution. 
Limiting dilution was performed by loading well-grown hybridoma clones into wells on 
96-well culturing plate in a serial dilution manner, until a concentration of 1-3 cells/well 
was reached. Wells with clones producing the tested positive antibodies were kept for 
further study. 
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2.2.7 Protein analysis 
2.2.7.1 Antibody collection, purification and biotinylation 
The supernatant in the 96-well culture plate was collected during the formation of 
hybridoma clones and used to test their antibodies activity against TERT antigens. Each 
well was taken and re-filled with fresh RPMI-1640 medium 3 times and all the 3 culture 
supernatant was kept and tested by ELISA. The wells that showed high readings in all the 3 
ELISA tests were considered positive and the cells were then transferred to large 
containers for further growth. 
After identification and dilution, hybridoma A63 cell line was kept in 6-well culture plate. 
This culture supernatant can be stored in 4°C，and used directly in ELISA test and Western 
Blot for antibody characterization. 
The antibodies in the culture supernatant were concentrated by ammonium sulfate 
precipitation. Hybridoma culture supernatant solution volume was determined and same 
volume of saturated ammonium sulfate solution was added to the supernatant slowly with 
stirring at the same time. Antibodies in the supernatant were precipitated out when the 
saturated ammonium sulfate solution was diluted to 50%. Precipitated antibodies were 
recovered in 1/10 of original volume of PBS and were dialyzed against PBS solution 
overnight at 4 °C. 
Antibodies were also purified using affinity 'protein-G sepharose column. Protein-G 
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sepharose beads were pre-packed to a 5ml column according to the manufacturer's 
instructions. Culture supernatant was collected, filtered and loaded on the column. After 
loading into the column, pipet up and down to make the column beads mixed well with the 
supernatant solution. Refill the column with culture supernatant to keep the sepharose from 
being dried. After all the samples flowed through the column, PBS was used as washing 
buffer to wash away non-specific bound molecules three times by washing of 10 times bed 
volume of the protein-G gel beads. The IgG antibodies bound on the beads can then be 
eluted out using 0.1 M Glycine/NaOH (pHll) solution. The eluted antibodies fraction was 
determined by reading absorbance at 260nm and neutralized with IM Tris-HCL (pH 6.8). 
The fractions with higher absorbance reading were collected together and dialyzed against 
PBS at 4 °C overnight. After dialyzed, the purified antibody solution was determined by 
BCA assay and stored at -20 °C before use. 
Purified antibodies were biotin-labeled as follows. Img of antibody was dialyzed (or 
diluted) in O.IM NaHCOs, pH 9.6 in 1ml solution at 4°C. N-hydroxysuccinimide-Biotin 
(Sigma) was freshly dissolved in DMSO to a concentration of Img/ml. Then, 75ul of 
dissolved biotin-NHS was mixed with Img/ml antibody solution in the bicarbonate buffer, 
and rolled at room temperature for 4 hours. Then the protein was dialyzed overnight in PBS 
at 4°C. The conjugates were stored at -20 °C before use. 
2.2.7.2 Electrophoresis and transfer of protein to membrane 
Induced bacterial expressed antigen was collected and purified by Glutathion-S-transferase 
purification column. The protein concentration was determined by using BCA assay kit. 
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All the samples from uninduced control lysate, induced lysate sample, purified protein 
sample were then mixed with 1/3 sample volume of 4X protein loading dye (with 2 % 
P-mecaptoethanal), boiled for 5mins, and analyzed by SDS-PAGE and Western blotting. 
Samples were loaded on 10%-15% sodium dodecyl sulfate-polyacrylamide gel 
(SDS-PAGE), depending on the molecular weight (MW) of the proteins to be detected. 
Electrophoresis was performed at room termperature at 150V, for 1.5 hours. The molecular 
weight was calibrated with prestained BenchMark protein ladder (Invitrogen, Carlsbad, 
CA, US). After electrophoresis, the gel was stained with coomassie blue to visualize the 
protein band at the expected size or was transferred onto a PVDF membrane. To transfer, 
the gel was placed on a methanol pre-wetted PVDF membrane (BioRad) and applied to a 
20V voltage in the semi-dry transfering cell (Trans-blot SD, BioRad) for 40min. 
2.2.7.3 Western blotting 
The PVDF membrane with transferee! protein on it was blocked by 5% non-fat milk in PBS 
(w/v) for 1 hour at room temperature. Non-specific binding sites on the membrane were 
blocked and primary antibody diluted in blocking buffer (5% non-fat milk in PBS) was 
then added to the membrane. The dilution fold changed by the stock solution concentration 
of antibody used. In specific term, culture supemat 1:2，purified mAb 1:500，mouse serum 
1:200, ascite fluid 1:1000 was used in experiments. The incubation conditon was overnight 
reaction at 4°C with gentle rocking. After washing with PBS-T for three times, lOmins 
each, the membrane was then incubated with secondary antibody diluted in the same 
blocking buffer for 1-2 hours. If secondary antibody was anti-mouse Igs-HRP, the dilution 
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used was 1:1000. After washing with PBS-T for at least an hour, the membrane was 
detected by ECL detection reagent (40 parts of solution A for 1 part of solution B) 
(Amersham Bioscience) and exposed to X-Ray film for 1 minute. 
2.2.8 Flow cytometry 
N-TERT antigens were biotin labeled using the same biotinylation method as antibodies 
(see 2.2.7.1). Cells for flow cytometry were allowed to grow into large number; 2-5 xlO^ 
cells were collected for each kind of cell. For mouse spleen cells, take all the cells to do the 
staining. 
Hybridoma cells were first harvested and washed with ice-cold PBS. PBS containing 1% 
FBS and 0.05% sodium azide washing buffer was then used. The azide was then washed 
away by two washing using ice-cold PBS. After that, cells were then fixed with 2% 
formaldehyde for 20mins on ice. A treatment using permeable buffer, which was made of 
PBS containing 2% FCS plus 1% saponin, for lOmins followed by a washing using 
ice-cold PBS to remove formaldehyde. After that, biotin-labeled N-TERT antigen was 
diluted to 0.1 mg/ml in PBS and used to stain the cells for 30mins, ice incubated. Following 
a 2 times washing using ice-cold PBS, secondary antibody, streptavidin-FITC，1:50 diluted 
in PBS, was then used to stain the cells, 20mins, on ice. Stained cells were kept in ice 
incubation after 2 times ice-cold PBS washing. The cells were then re-suspended in FACS 
buffer (PBS, 2% BSA，1 mM EDTA). Direct staining using anti-mouse Ig -FITC to 
hybridoma cells was used as positive control, and the operation was same as secondary 
antibody. FACS analysis was performed in 3-4 hours. 
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For mouse spleen cells, the prepary steps are same as making hybridomas. An anti-CD 19 
monoclonal antibody conjugated with PE molecule only recognizing B cell population was 
used to help identifying the B cell population. Other staining protocol was same as the one 
used in hybridoma staining. In the gating step during FACS analysis, an extra defining step 
for the B population was required. 
2.2.9 Animal handling 
Female normal Balb/c mice of 8-12 weeks old were used in both immunization for 
production of hybridoma and the production of ascite fluid. 
In hybridoma production, each Balb/c mouse was first immunized with 500ng antigen 
(both N-TERT and C-TERT) with complete Freund's adjuvant intra-peritoneally (IP), 
followed by two intra-peritoneal boost with 500ng/mouse with incomplete Freund's 
adjuvant two weeks later. At last, the mice were immunized with 50ng/mouse 
intravenously (IV) 3 days before fusion. 
For ascite fluid producition, Balb/c mice were first primed with 0.5ml IFA for each mouse 
by peritoneum injection. After washed in PBS, well-growing hybridoma cells were 
collected and injected into the mice intra-peritoneally with a concentration 2-5 million cells 
per mouse. After two weeks, the mice develop ascite fluid were sacrificed and the ascite 
fluid was collected. The antibody activity of ascite fluid was determined by ELISA and the 
antibodies in the ascite fluid were concentrated by ammonium sulfate precipitation or 
purified by protein-G sepharose chromatograpHy. 
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2.2.10 Statistical analysis 
Statistical analysis of experiments was performed by statistical software-SPSS. One-way 
ANOVA (nonparametric) or students' t-test was used in different conditions. The values 
were mean 士 SE of triplicate determinations and the results were consolidated from three 




Preliminary studies using the anti-N-TERT-telomerase mAb 
derived from hybridoma 476 
3.1 Preamble 
Telomerase is important as a housekeeping enzyme in cells and as a tumor marker as it is 
up-regulated in cancer cells. Based on that, monoclonal antibodies to this protein can be an 
important and effective tool to use in detecting and the killing of cancer cells. Previous 
studies done in this regard in our laboratory by Dr. Danny Leung and Dr. Niu Haitao had 
used a hybridoma called 476 that they produced, which makes a monoclonal antibody 
against the N-terminal end of the human telomerase catalytic subunit (TERT). Hybridoma 
476 cells produce an IgGl monoclonal antibody that recognizes both the recombinant and 
natural forms of human telomerase. Besides, this antibody also recognizes mouse 
telomerase (Leung et al. 2005) as well as the telomerase enzyme from the marine medaka 
fish {Oryzias melastigma) (Kong et al. 2008). Human TERT protein sequence contains 7 
transcriptase motifs (1，2 and A-E) and a telomerase-specific motif (T), which are 
conserved in different organisms (Nakamura et al. 1997; Weinrich et al. 1997; Nakamura 
and Cech 1997). Motifs T，1 and 2 are located in the N-terminal end of TERT that was used 
to produce the mAb 476. 
An interesting finding about hybridoma 476 was that hybridoma 476 cells could not grow 
to produce ascites fluid in the normal Balb/c mice peritoneum although it could survive and 
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secrete antibodies in culture (Niu et al. 2008). 
Based on the conclusion reached by previous investigators (Niu et al. 2008)，hybridoma 
476 cells die due to the presence ofIL-6 in the primed peritoneum. An interesting question 
that I investigated at the beginning of my studies was: if we inject IL-6 to N-TERT 
immunized mice, would those anti-N-TERT antibody-producing B cells die as a result? 
This question was totally new. 
This would be a very complex study and my contribution to answer this question was to 
find an assay to monitor the effect of the IL-6 therapy. We needed to count the number of 
the N-TERT-specific antibody-producing cells in mice, from among the whole 
antibody-producing cell population in the spleen. 
To do that, I decided to establish a new technique which used a labeled recombinant 
N-TERT antigen to stain the autoantibody producing cells in the N-TERT immunized mice, 
and enumerate the cells by flow cytometry (FACS). 
3.2 Hybridoma 476 cells can be stained by the labeled recombinant 
N-TERT antigen 
Several flow cytometry experiments were perfomed using cultured hybridoma cells. 
Purified recombinant N-TERT antigen labeled with biotin was used to stain these 
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hybridoma 476 cells. These cells were harvested at a 2x10^ cells/ml concentration and 
arrested by azide. Another hybridoma, Mab 2, and the hybridoma fusion partner, SP2/0 
cells were used as control. For staining, the cell membrane was first permeablized by 
saponin-containing buffer with 10% fetal calf serum (FCS), and then the cells were 
incubated with the biotin-labeled antigen. After washing and incubation with streptavidin 
(conjugated with green fluorescence, FITC), the cells were examined by FACS (FL-1 
channel). 
In each experiment, the cell population to be analyzed was first identified by their cell size 
(FSC channel) and granularity (SSC channel). The selected population contained the 
majority of the hybridoma cell population, and all the samples in each experiment were 
gated by an identical standard (Rl). Of all the selected hybridoma cells were then analyzed 
according to their fluorescence signal. (Figure 3.2A) 
By comparing the results obtained from hybridoma 476 to those of the control hybridoma 
Mab2 and the SP2/0 cells, we could see clear evidence that biotin-labeled N-TERT antigen 
was specifically bound by the anti-telomerase antibodies inside the hybridoma 476 cells 
(Fig 3.2 B，C, and D). Thus, 35.4% of the hybridoma 476 cells were stained, compared to 
0.5% and 0.35% for the Mab2 cells (Figure 3.3) and SP2/0 cells (Figure 3.4)，respectively. 
Moreover, the reactivity in the hybridoma 476 cells was reduced dramatically to 1.45% 
when unlabeled N-TERT antigen was used to block the reaction. 
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3.3 Mouse spleen cells can also be stained by biotin-labeled N-TERT 
antigen 
A total of 6 mice were immunized with N-TERT-GST antigen and their antibody response 
to telomerase was examined by ELISA against purified N-TERT antigen. The results show 
that antibodies to telomerase rather than GST were produced by all animals (Figure 3.1). 
After that, three of these 6 mice were sacrificed and their spleens were taken out and 
crushed for staining. The staining protocol was similar to the one used for hybridoma cells 
staining. However, in order to separate the active antibody-producing B-lymphocytes from 
other cells in the spleen such as T cells and macrophages, another probe was used. This was 
the CD 19 marker, which was labeled with propidium iodide (PI), and which stained B cells 
only. Thus we first selected the lymphocytes population (Rl) based on size and granularity 
(FCS channel and SSC channel) (Figure 3.5A). After that, based on anti-CD 19 (PI) signal 
(FL-2 channel), two peaks, and one represented B cells, and another, for other cells, were 
identified (Figure 3.5C). By choosing the B cell population only (high reading in CD-19 PI 
signal, gated as R2) (Figure 3.5D), we then used FL-1 channel for fluorescence signal 
analysis. 
All 3 mice immunized with N-TERT antigen had more B cells stained by N-TERT antigen 
than the 3 normal mice used as control (Fig 3.6). Thus, 10.10% 土 2.78% of the immune 
mice cells were stained with N-TERT antigen, while only 1.93%士 0.3% of the normal mice 
cells were stained (Figure 3.7). The hypothesis was statistically tested by a Students' t-test 
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using SPSS, which showed that there was significantly (p<0.05) more B cells from 
N-TERT immunized mice that were stained than those from normal mice. 
3.4 Discussion 
I have developed a FACS method to enumerate the N-TERT specific antibody producing 
cells in mouse spleen. This method is useful for investigating whether the auto 
antibody-producing cell population can be manipulated in mice when these animals are 
treated with immune-enhancing drugs like IL-6. I have not continued with further 
experiments in this area because of time limitation. Also, the present method needs to be 
improved further because there appears to be a high background of staining. Moreover, the 
sensitivity of the assay needs to be increased because the positive cells appeared to be only 
weakly stained. 
Although the question of whether of IL-6 could be used to kill auto-antibody producing 
cells, and the technique of using FACS to count these cells, are new, other methods have 
been used to detect antibody-producing cells previously. These assays include the 
plaque-forming cell (PFC) assay, using sheep red blood cells (SRBC) coated with the 
antigen of interest to detect single antibody-producing B cells in the form of hemolytic 
plaques that formed in an agarose medium (Jeme and Nordin 1963; Mishell and Dutton 
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1967). However, this technique requires strict control conditions and artifacts could arise 
easily. It is an old technique, which is with less used nowadays. A new assay method is 
called ELISPOT (marketed by AID, Strassberg, Germany), which uses the principle of the 
ELISA (Czerkinsky et al. 1983) to detect antibody-producing cells. This technique has 
higher accuracy and specificity, and is widely used in immunological research especially 
for cytokine studies. In this method, in order to detect the antibody producing cells, the 
particular antigen is coated on a plate and blocked by proteins. The antibody producing 
cells are cultured at limiting dilutions such that each well contains a single cell, and 
allowed to be incubated with the coated antigen, either after antigenic stimulation or not. 
The cells will then be washed away, and the antibodies produced bind to the coated antigen 
and are detected by a secondary antibody conjugated with HRP or AKP enzyme. 
Following the addition of the appropriate colorimetric substrate, the reaction is visualized 
in the form of 10-20 mm coloured dots on the plate. 
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(Blocked by OPNa-GST) 
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Figure 3.1 Characterization of N-TERT immunized mouse serum by ELISA. N-TERT 
immunized mouse serum was used to bind to N-TERT antigen (coated at 300 ng/ml) and 
blocked by OPNa-GST (at 10 ug/ml). The results demonstrated that the N-TERT 
immunized serum activity against N-TERT only mildly affected by GST, even with much 
higher concentration of the coated N-TERT antigen (>30 fold), indicating the strong 
activity of N-TERT immunized mouse serum against effective part of the N-TERT antigen, 
rather than GST. 
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Figure 3.2 FACS analysis ofhybridoma 476 cells stained with labeled N-TERT antigen. A) 
Population of cells (Rl) selected by size and granularity used for study. B) Analysis of 
cells stained with N-TERT. C) Analysis of cells stained with N-TERT but blocked with 
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Figure 3.3 FACS analysis of Mab2 (control) hybridoma cells stained with labeled 
N-TERT antigen. A) Analysis of cells stained with N-TERT. B) Analysis of cells stained 
with N-TERT but blocked with un-labeled N-TERT. C) Unstained cells (negative control). 
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Figure 3.4 FACS analysis of SP2/0 (control) myeloma cells stained with labeled 
N-TERT antigen. A) Analysis of cells stained with N-TERT. B) Analysis of cells stained 
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Figure 3.5 Gating conditions for FACS analysis of spleen cells from N-TERT immunized 
mice stained with labeled N-TERT antigen. A) Population of cells (Rl) selected according 
to size and granularity. B) Profile of selected Rl cells stained with N-TERT. C) Profile of 
selected Rl cells stained with anti-CD 19 antibody conjugated with PI. D) Sub-population 











Figure 3.6 FACS analysis of splenic B cells from an N-TERT immunized mouse or a 
normal mouse, stained with labeled N-TERT antigen used at 1:10 (A) or 1:25 (B) of stock 
solution. Unstained cells are shown in (C). 





N-TERT immunized mice Normal mice 
Figure 3.7 FACS data statistical analysis of splenic B cells from N-TERT immunized mice 
and normal mice, stained with labeled N-TERT antigen used at 1:10 dilution. Values are 
mean 士 SE of 3 mice in each group, indicated by the vertical bars. Statistically different 




茨 2 0 % 
•w 连 o 0 
•D 





Production of monoclonal antibodies to C-TERT 
4.1 Preamble 
Production of an anti-telomerase monoclonal antibody requires the generation of a 
hybridoma that can produce this type of antibody. The technique used for making 
hybridomas is well developed which was invented by Cesar Milstein and Georges Kohler 
in 1975. For this technique, it is required to first produce the telomerase antigen and then 
use it to immunize Balb/c mice. 
4.2 Construction of C-TERT expression vector 
The method used for the construction of a C-TERT expression vector was same as the one 
used for N-TERT (Leung et al. 2005). A TERT cDNA fragment was generated from the 
mRNA ofHL-60 cells by RT-PCR (Leung et al. 2000) using a pair of primers BTUppl and 
BTLow2, each containing one restriction site. This gene segment of human TERT 
encoding the recombinant C-TERT antigen is indicated in Fig 4.1，which contains the 
frontier part of the C-terminal part of the telomerase protein. The protein sequence was 
compared to mouse TERT using online alignment programme CLUSTALW at 
http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_server.html (Figure 
63 
4.2). This segment was digested by restriction enzyme EcoRI and BamHI and then cloned 
into a plasmid vector. The plasmid used for cloning and expressing C-TERT in BL21 
E.coli is pGEX-2T, obtained from a commercial kit. The genetic map of pGEX-2T vector 
is shown in Figure 4.3. 
4.3 Expression and purification of recombinant human C-terminal 
telomerase antigen 
The pGEX-2T plasmid containing the correct ligated C-TERT cDNA segment was used to 
transform into BL 21 Escherichia coli by electroporation. Clones with correct insert was 
selected on Ampicilin resistant medium, and confirmed by analyzing the inserting 
fragment size and sequence. 
The expressed TERT antigen was produced as a fusion protein with GST in E.coli and was 
purified using a GST-affinity column. It is expected to be a protein with estimated 
molecular mass of 26 kDa. Induced bacterial lysate containing the expressed C-TERT 
antigen and purified antigen was analyzed by Coomassie blue staining on 12% SDS-PAGE 
(data shown later). 
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4.4 Immunization ofBalb/c mice with C-TERT-GST 
The affinity purified C-Tert antigen was used to immunize Balb/c mice. The antibody 
activity of the serum obtained from immunized mice was assayed by ELISA (Figure 4.4). 
The result shows that the C-TERT immunized mouse serum was strongly reactive against 
the purified C-TERT antigen, while the control N-TERT immunized mouse serum as well 
as control normal mouse serum were either not reactive or weakly reactive only. 
4.5 Generation of hybridomas to C-TERT 
Hybridomas were produced by fusion using the spleen cells from the strongest responding 
mouse and NSO cells (Wun et al. 2001). Spleen cells from normal mice were used as feeder 
cells. Selective medium containing HAT was used to select for hybridomas one day after 
fusion. After 2-3 weeks, fusion clones were observed. About 30% of the wells on four 
96-well plates were positive for clones (Figure 4.5). 
4.6 Identification and selection of reactive clones 
The clones formed were examined by ELISA tests for activity against C-TERT. Clones 
with the strongest activity were selected and subcultured into large flasks. Later, limiting 
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dilution was performed by plating 1-3 cells in each well on the 96-well plate. After 6 fusion 
attempts, a clone was found to be consistently active against C-TERT in ELISA (Figure 
4.5). This clone, called A63，produced an IgG antibody and was chosen for further study. 
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N-TERT 378bp C-TERT 309bp 
Figure 4.1 Map of telomerase catalytic subunit (TERT) showing the various motifs. The 
378 bp segment shown is used for cloning of N-TERT antigen to raise mAb 476; the 309 
bp segment shown is used for cloning of C-TERT antigen to raise mAb A63. 
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Figure 4.2 Comparison of protein sequences of C-TERT segment, between human 
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Figure 4.3 Map of the pGEX vector. Glutathione S-transferase-(GST), selection marker 
the origin of replicate (pBR322 ori) and the multiple cloning site containing various 
restriction sites are shown. The C-TERT gene was inserted using the restriction sites of 
EcoR I and BamH I. 
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Figure 4.5 Antibody activities against C-TERT antigen of 6 different clones. The culture 
supernatant from each clone was examined by ELISA used against C-TERT (coated at 300 
ng/ml). The measurements made initially (First ELISA) were repeated after 4-6 days 
(Second ELISA). Signal threshold used for scoring positive is 1.5 (OD 450nm), while OD 
450nm readings below 1.5 is indicated as “-“，1.5-2.0 indicated as “+，，，2.0-2.5 indicated as 
“++，，，and reading above 2.5 is indicated as “+++，，. Serum from C-TERT immunized 
mouse is used as positive control (diluted 100 fold). 
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Chapter Five 
Characterization of mAb A63 
5.1 Preamble 
A stable clone called A63 was obtained which produced a monoclonal anti-C-TERT 
antibody. The antibodies produced in the culture medium were concentrated by 
ammonium sulfate precipitation and further purified using protein-G column. These 
purified antibodies, the protein content of which was determined by the BCA assay, were 
used for various characterization studies. 
5.2 Characterization of mAb A63 by ELISA 
Purified recombinant C-TERT antigen coated on ELISA plates was used to examine the 
activity of mAb A63 by direct ELISA, with mAb 476 and Mab2 antibodies used as control. 
Protein-G purified mAbs were used in these experiments. mAb A63 and mAb 476 were 
also biotin-labeled and used in some experiments. The results showed that mAb A63 had 
very strong activity against purified C-TERT antigen, while mAb 476 and the negative 
control Mab2 antibody were either negative or weakly positive (Figure 5.1). 
Purified recombinant N-TERT antigen was used to check the specificity of mAb A63. 
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mAb 476 and serum from N-TERT immunized mice were used as control. The results 
showed mAb 476 and the N-TERT immunized mouse sera were strong in reactivity to the 
N-TERT antigen, while mAb A63 had only background activity against N-TERT (Figure 
5.2). 
The mAb A63 specificity was also determined using purified OPNa-GST antigen as 
substrate. The results show that mAb A63 binds to C-TERT antigen well but did not bind 
to OPNa-GST, which means that A63 was specific to C-TERT and not GST (Figure 5.3). 
mAb A63 was then biotin-labeled to test its activity against C-TERT antigen following 
inhibition by various types of antibodies or antigen. First, various kinds of antibodies were 
used (Figure 5.4). The results show the binding between biotin-labeled mAb A63 and 
C-TERT was inhibited by non-labeled mAb A63 and serum from C-TERT immunized 
mice. As control, normal mouse serum, mAb 476 and Mab2 did not inhibit the binding. 
This inhibition effect showed a real and specific binding between mAb A63 and the 
C-TERT antigen. 
Specificity of mAb A63 was also examined by using various antigens to inhibit the binding 
between C-TERT antigen and biotin-labeled mAb A63. The antigen was first 
pre-incubated with biotin-labeled mAb A63 for a period of time, and the mixture was then 
added and allowed to react with coated C-TERT antigen. The results (Figure 5.5) show that 
C-TERT antigen inhibited the binding remarkably, while N-TERT, OPNa-GST and BSA 
had little or no inhibition effect. This result confirmed the high specificity between 
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C-TERT and mAb A63. 
5.3 Characterization of mAb A63 by Western blotting analysis 
Recombinant C-TERT antigen was loaded into SDS gel and then transferred onto a PVDF 
membrane. Later, mAb A63 culture supernatant was used as the antibody source to stain 
this membrane. Uninduced bacteria extracts were used as control antigens. The results 
show that mAb A63 recognized the recombinant C-TERT antigen specifically, but not the 
antigens in the un-induced bacteria extracts (Figure 5.6). 
5.4 Characterization of mAb A63 by immuno-histochemical staining 
Purified mAb A63 was used to stain formalin-fixed human HL-60 cells with or without the 
help of Enhancing buffer, together with mAb 476 and Mab2 used as control. The results 
show that a nuclear staining pattern for mAb 476 and mAb A63 when the Enhancing buffer 
was used, but no cytoplamic staining (Figure 5.7). The control Mab2 antibody did not stain 
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the HL-60 cells (Figure 5.7). Experiments done without the use of the Enhancing buffer 
showed that both mAb 476 and mAb A63 only stained the cytoplasm rather than the 
nucleus of the fixed HL-60 cells (Figure 5.7). 
DMSO treatment can cause reduction in the cell metabolism activity, including 
down-regulated telomerase activity. Thus, 0.5% DMSO containing RPMI medium treated 
HL-60 cells were harvested, fixed by formalin and then stained by mAb 476 and mAb A63 
with the help of Enhancing buffer (Figure 5.8). The results show that the staining signal 
decreased dramatically in the treated cells. For mAb 476，about 20% of cells were not 
stained, while the rest of the cells were only weakly stained. For mAb A63, over 90% of the 
HL-60 cells were not stained. 
Inhibition tests were also performed with the immuno-histochemical staining method. 
Formalin-fixed HL-60 cells pre-incubated with C-TERT，N-TERT and BSA for a period of 
time were stained by mAb A63 labeled with biotin. In this way, the binding between the 
biotin-mAb A63 and the coated telomerase antigen was found to be inhibited by 
recombinant antigen C-TERT but not by N-TERT antigen or BSA (Figure 5.9). This 
inhibition is a clear evidence that mAb A63's binding to C-TERT antigen is specific. 
The hybridoma fusion partner NSO cells, which are mouse cells, were also used to check 
for telomerase binding by mAb A63. Thus, NSO cells were harvested, fixed by formalin 
and then stained by purified mAb A63 or mAb 476 with the help of Enhancing buffer. 
Interestingly, mAb A63 and mAb 476 stained differently for this kind of cell (Figure5.10). 
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While mAb 476 stained NSO cells very well, mAb A63 failed to stain these cells. Thus, 
mAb A63 is only with single human specificity, but lack the cross-reactivity with 
mouse-TERT. 
5.5 mAb A63 can also stain fish telomerase and human placenta 
Another source of telomerase was also used to check the binding activity of mAb A63. 
Previously, mAb 476 was found to stain the telomerase found in marine medaka fish 
{Oryzias melastigma) (Au et al. 2008) with the help of Enhancing buffer. mAb A63 
similarly was reactive with fish tissues (Figure 5.11). However, the staining details are 
different between mAb 476 and mAb A63. As indicated in Figure 5.11, the muscle 
(somatic), ovary (reproductive) and intestine (degenerative) were clearly stained by mAb 
476，especially the nucleus of the cells. In contrast, mAb A63 stained the tissues with a 
higher background and more staining was also found in the cytoplasm. 
In another experiment, human third-trimester placental (TTP) tissue was used. This was 
pre-treated with methanol-hydrogen peroxide to block endogenous peroxidase activity 
followed by microwave treatment (Balaton et al. 1993). Human placental tissue is 
tumor-like with a high proliferative activity and telomerase is expected to be present in 
abundance. mAb 476 was found to stain both the cytotrophoblasts (CT) and the 
syncytiotrophoblasts (ST) (Rama et al. 2001), whereas mAb A63 stained only the CT layer 
(Figure 5.12). 
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5.6 mAb A63 can also stain telomerase in human tumors 
TERT activity is known to be present in most human tumor cells and tissues, as well as in 
human germ-line tissues, but not in most normal somatic cells. As described in the 
Introduction, TERT could be a useful tool for the early detection of cancer, both as a 
biomarker and as a potential target. mAb 476 was shown to be useful in detecting 
telomerase from human tumor tissues (Leung et al. 2005), and the present purpose of 
producing mAb A63 was to find out the answer to the question whether an antibody against 
TERT at the C-terminal end would work in the same way. Thus, mAb A63，together with 
mAb 476 were used in the present study to stain several tumor tissues, including 
nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC) and metastatic 
choriocarcinoma of the small intestine. Whereas mAb 476 showed strong reactivity against 
hTERT in the different types of tumor tissues, only mild staining was observed in the HCC 
sections with mAb A63 (Figure 5.14). Both mAb 476 and mAb A63 stained the perinuclear 
cells. No detectable signal was found with the NPC or metastatic choriocarcinoma sections 
using mAb A63, even with help of Enhancing buffer (data not shown). 
5.7 Hybridoma A63 can produce ascites fluid 
Production of ascites fluid in Balb/c mouse using hybridoma A63 cells was found to be 
possible. The picture of an ascites-forming mouse can be seen in Figure 5.15. Thus, of 4 
mice injected i.p. with hybridoma A63 cells, all of the mice developed ascites fluid after 14 
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days. From each of the mice, about 2 ml of ascites fluid were obtained. The ascites fluid 
had strong antibody activity as measured by ELISA. The ascites fluid collected was also 
used to stain HL-60 cells and human placenta sections (third trimester placental, TTP) 
(Figure 5.13). The results demonstrated that the crude mAb A63 preparation could stain the 
human telomerase protein in both HL-60 cells and human placenta sections. 
5.8 Discussion 
mAb A63 specifically stained the telomerase antigen in the nucleus of HL-60 cells, similar 
to the observations made using mAb 476. The specificity was confirmed using a control 
antibody, Mab2, which did not show any staining (Figure 5.7)，as well as the fact that 
DMSO also decreased the staining intensity of mAb A63 (Figure 5.8). Although both of 
the two monoclonal antbodies could be used to stain the telomerase antigen in medaka fish 
and human placental tissues，subtle differences could nonetheless be found between these 
two antibodies in these two tissues (Figure 5.11 and Figure 5.12). The reason for these 
differences could be varied and is not known exactly. The staining using mAb A63 for 
medaka fish was specific because it also stained the telomerase antigen in the nucleus. The 
most significant difference between mAb 476 and mAb A63 lies in the hybridoma cells 
that produce them: the ability or inability of these cells to form ascites. The ascites fluid 
obtained from A63 cells was found to be biologically active as it contained antibodies that 
could recognize the TERT protein in both HL-60 cells and human placenta. 
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Figure 5.1 Characterization of purified mAb A63 I. Purified and biotin-labeled mAb A63 
was examined by direct binding ELISA against C-TERT antigen coated at 300 ng/ml. 
Antibody stock concentration: 2.8 mg/ml for mAb 476，3.1 mg/ml for mAb A63, 3 mg/ml 
for Mab2, 2.9 mg/ml for biotin-mAb A63, 3 mg/ml for biotin- mAb 476. 
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Figure 5.2 Characterization of purified mAb A63 II. Purified mAb A63 and mAb 476 was 
examined by ELISA against N-TERT antigen coated at 300 ng/ml, using N-TERT 
immunized mouse serum as control. 
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Figure 5.3 Binding of purified mAb A63 on GST. C-TERT antigen and OPNa-GST 
antigen was coated at 0.2 ug/ml, mAb A63 stock solution concentration: 2.9 mg/ml. 
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Figure 5.4 Characterization of mAb A63 by inhibition ELISA. C-TERT antigen was 
coated at 300 ng/ml. Biotin-labeled mAb A63，s binding to recombinant C-TERT antigen 
was tested by competitive inhibitor: normal mouse serum, C-TERT immunized mouse 
serum, purified mAb A63 (not biotin-labeled, self-inhibition control), purified mAb 476 or 
Mab2 antibody (negative control). Biotin-mAb A63 was used at 10 ng/ml. Inhibiting 
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Figure 5.5 Binding ofmAb A63 to C-TERT antigen (coated at 300 ng/ml) by inhibition 
ELISA. Inhibitor used: purified recombinant C-TERT antigen, N-TERT antigen, 
OPNa-GST and BSA (negative control). Biotin-mAb A63 was used at 10 ng/ml. Inhibiting 
antigens stock concentration: C-TERT: 1.7 mg/ml, OPNa-GST: 1.85 mg/ml, N-TERT: 2.1 
mg/ml, BSA: 2 mg/ml. 
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Figure 5.6 Western blotting (WB) results showing C-TERT recombinant antigen 
(indicated by arrow) in E.coli extracts stained by mAb A63. Also shown are the 
Coommassie blue-stained SDS-PAGE gel of the E.coli extracts. E.coli extracts were 
derived from hosts transfected with C-TERT plasmid, either uninduced (lane 1) or induced 






























































Figure 5.7 Formalin-fixed HL-60 cells (40x) reacted with mAb 476, mAb A63 or Mab2 
(all purified, plus goat anti-mouse Ig-HRP, developed with DAB, and counterstained with 
H&E), demonstrating cytoplasmic or nuclear staining (brown) when normal or Enhancing 
buffer was used, respectively. Arrows indicate the nuclear stained cells. 
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Figure 5.8 Formalin-fixed HL-60 cells (40x) reacted with mAb 476 or mAb A63 (both 
purified，plus goat anti-mouse Ig-HRP, developed with DAB, and counterstained with 
H&E)，demonstrating the effect of DMSO treatment on telomerase expression. Enhancing 











Figure 5.9 Formalin-fixed HL-60 cells (40x) reacted with mAb A63 (biotin labeled, plus 
streptavidin-conjugated HRP, developed with DAB, and counterstained with F^ &E)， 
following co-incubation with N-TERT, C-TERT or control BSA. The results demonstrate 
the specific inhibitory effect of C-TERT against binding between mAb A63 and 
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Figure 5.10 Formalin-fixed NSO cells (20x) reacted with mAb A63 or mAb 476 (purified 
plus goat anti-mouse Ig-HRP, developed with DAB, and counterstained with H&E). The 
results demonstrate the inability of mAb A63 to stain mouse telomerase, unlike mAb 476 
Enhancing buffer was used in both cases. ‘ 
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Figure 5.11 Fixed female marine medaka fish {Oryzias malastigma) section reacted with 
mAb 476 and mAb A63 (both purified, plus goat anti-mouse Ig-HRP, developed with DAB, 
and counterstained with H&E) (Photos were taken with lOx objective & optically enlarged 
to 40x by computer software). Different organelles of the sections (indicated by arrows) 
were stained —muscle (somatic), ovary (reproductive) and small instestine (regenerative). 
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Figure 5.12 Fixed human placental section (40x) reacted with mAb A63 or mAb 476 (both 
purified, plus goat anti-mouse Ig-HRP, developed with DAB, and counterstained with 
H&E). Enhancing buffer was used in both cases. Both mAb 476 and mAb A63 stained only 
the inner layer (CT layer). ST =syncytiotrophoblast layer, CT =cytotrophoblast layer. 
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Figure 5.13 Fixed human TTP section (lOx) and fixed HL-60 cells (lOx) reacted with 
purified mAb A63 or crude mAb A63 (ascites fluid diluted 1:2000) (plus goat anti-mouse 
Igs-HRP, developed with DAB, and counterstained with H&E) and Enhancing buffer was 





Figure 5.14 Fixed human liver sections from hepatocellular carcinoma patient reacted 
with mAb A63 or mAb 476 (purified, plus goat anti-mouse Ig-HRP, developed with DAB, 
and counterstained with H&E). Enhancing buffer was used in all cases. Arrows indicate the 
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Figure 5.15 Picture of a normal Balb/c mouse with ascites formation (left), indicated by 





My study was based on the production and characterization of a monoclonal antibody 
against the C-terminal end of hTERT (C-TERT)，which was used to understand the 
behaviour and characteristics of another anti-telomerase antibody called mAb 476，an 
IgGl antibody raised previously to the N-terminal end of the hTERT protein (N-TERT). 
Previous studies performed in our laboratory (Leung et al. 2005; Niu et al. 2008)，showed 
two unusual features about mAb 476: 
1. mAb 476 was able to stain human telomerase in the nucleus of various types of 
cells but only with the help of a special retrieval buffer called Enhancing buffer. 
Without the Enhancing buffer, cytoplasmic staining, instead, was observed. 
This staining pattern appeared with both the human cell line, HL-60, and with 
human tumor cells, both of which have up-regulated telomerase levels. Besides, 
mAb 476 was also able to stain the telomerase from mouse and that in the 
marine medaka fish (Oryzias melastigma), both only in the presence of 
Enhancing buffer. This telomerase staining pattern is unique and differs from 
those of other known anti-telomerase antibodies, as published by other 
investigators (Wada et al. 2000; Tahara et al. 1999). Considering the normal 
biological function of telomerase, this nuclear staining found with mAb 476 
could only be real and, moreover, Western blotting studies also identified 
TERT in the nuclear extracts but not the cytoplasmic extracts of various types 
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of cells (Martin-Rivera et al. 1998; 
mAb 476 failed to grow to form ascites in the normal Balb/c mice peritoneum. 
This is unlike all other mouse hybridomas used in our laboratory, which readily 
produced ascites. It was discovered that the mAb 476-producing hybridoma 
cells committed suicide when administrated to the primed Balb/c mice 
peritoneum. Further studies identified an important cytokine, IL-6，that 
appeared to play a critical role in this issue. This cytokine appeared to increase 
the antibody synthesis in the cell, which consequently increased the 
intracellular binding between the antibodies and the auto-antigens (telomerase), 
hence leading to cellular apoptosis (Niu et al. 2008). 
My study started on seeking the reasons why mAb 476 and its hybridoma have these two 
unique features. In order to do that, I constructed another anti-hTERT antibody, called 
mAb A63, raised to another part of the hTERT protein, the C-terminal end. This 
C-TERT-specific antibody was produced and characterized together with mAb 476 using 
various types of immunoassays. mAb A63 was able to recognize the recombinant C-TERT 
antigen in ELISA tests and in Western blotting (Figure 5.1-5.6). More importantly, the 
results of the immunohistochemical tests performed on HL-60 cells using mAb A63 
appeared to be very similar to the ones obtained using mAb 476. That is, mAb A63 stained 
the HL-60 cell nucleus only with the help of the Enhancing buffer, whereas only the 
cytoplasm was stained when normal buffer was used (Figure 5.7). Both mAb 476 and mAb 
A63 cells showed a reduction in the stained telomerase signal when these cells were treated 
with DMSO (Figure 5.8). This result agrees with the effect of DMSO treatment described 
previously by other investigators, notably, that DMSO treated HL-60 cells showed 
decreased telomerase mRNA expression and the loss of telomerase enzymatic activity 
(Sharma et al.l995). The similarity between mAb 476 and mAb A63 also extends to their 
ability to bind to the telomerase antigen found in the marine medaka fish {Otyzias 
melastigma) and human placenta. 
The above findings offer a greater insight into the behaviour of mAb 476 and its hybridoma, 
and this is discussed in greater detail below. 
6.1 Why Enhancing buffer is required for the nuclear staining of 
hTERT when using mAb 476 or mAb A63 
Conventional antigen retrieval methods include changing of the buffer pH (Shi et al. 1995), 
use of proteolytic enzymes, and the use of microwave irradiation as pre-treatment (Leong 
1996). These methods work by breaking the protein cross-linkages in the tissues fixed by 
aldehyde. These cross-linkages can mask the epitopes of interest. The rigid cage-like 
calcium complex formed during formaldehyde fixation is another possible reason of 
epitope masking, which can also be cleaved by these methods (Leong and Leong 2007). 
Microwave irradiation works by generating high temperatures that can break down the 
protein cross-linkages between proteins or the cage-like calcium complex. Microwave 
irradiation can also trigger extremely rapid molecular movement, which can break down 
the "mask" on antigens. It was shown that microwave irradiation of paraffin-embedded 
sections bathed in 10 mM citrate buffer dramatically increased the intensity of the 
immunostaining of various types of tissue antigens (Leong 1996). Thus, microwave 
irradiation for epitope retrieval is not only a signal-enhancing step for 
immunohistochemical staining, but has also become a standard step for immunostaining. 
Although microwave irradiation is the standard of antigen retrieval, it is known that some 
chemicals or the pH of the antigen retrieval buffer can also affect the staining. Thus, pH 
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value of antigen retrieval buffer can generate significant differences with some mAbs, 
whether the nuclear or cell surface antigens are stained in formalin-fixed, 
paraffin-embedded sections (Shi et al. 1995). This is because some cross-linkages can be 
hydrolyzed under certain pH conditions (usually alkaline), similar to proteolytic enzyme 
treatment e.g. the use of pepsin. 
However，as found in my study, there are still some situations where the above-mentioned 
antigen retrieval methods do not work, because of the complex function or localization of 
these antigens, such as telomerase. Work done in our laboratory shows that microwave 
irradiation is not able to retrieve telomerase from HL-60 cells or human tumor cells (Ma et 
al., unpublished observations). The use of the Enhancing buffer is thus a new method in 
antigen retrieval. The working mechanism of the Enhancing buffer is discussed further 
below. 
It was a puzzling finding that, when mAb 476 was first used to stain HL-60 cells and 
human tumor cells, only cytoplasmic staining was observed when normal buffer was used. 
Nuclear staining was possible, however, but only with the help of the Enhancing buffer, 
which presumably retrieves the telomerase antigen from inside of the nucleus. It seems that 
this buffer functions by separating the enzyme from associated proteins bound to it (Figure 
6.1)，or it loosens the nuclear matrix and thus exposes the enzyme (Figure 6.2). 
As introduced in Chapter one, TERT exists as a functional enzyme in association with the 
RNA component, TERC (Lai et al. 2001; Etheridge et al. 2002), as well as with other 
97 
protein factors such as hStau, L22 (Le, S. et al. 2000)，and TEP 1 (Nakayama et al. 1997). 
Chaperone proteins were also found to associate with the telomerase complex, like p23 and 
hsp90 (Holt et al. 1999). In theory, these proteins can block the epitope in TERT and 
prevent binding of mAb 476. However, since the Enhancing buffer pretreated HL-60 cells 
did not allow mAb 476 to stain the enzyme in the nucleus in these cells under normal buffer 
staining conditions (Leung et al. 2005), it seems that the Enhancing buffer functions by 
temporarily opening up the nuclear matrix rather than dissociating the accessory proteins 
from TERT. This is supported by my present study using mAb A63. This antibody 
recognizes an epitope in the C-terminal end of TERT which is not bound by any accessory 
proteins. Since mAb A63 was able to stain the nuclear telomerase in HL-60 cells only 
when the Enhancing buffer was used, this suggests that the whole TERT protein is 
normally well buried inside the nucleus and is inaccessible to any antibody probe (Figure 
6.2). This is also consistent with the fact that other nuclear antigens could also be retrieved 
effectively by the Enhancing buffer. For example, a nucleolar RNA antigen in Hep2 cells 
was stained by anti-guanylyl antibodies only when using the Enhancing buffer (Ma et al. 
2004). It should however be noted that there are many other nuclear antigens, such as 
double standed DNA (dsDNA) and La, that can be bound by the appropriate antibodies in 
normal buffer without the use of retrieval agents. 
The detection of the telomerase enzyme in both the cytoplasm and nucleus by both mAb 
476 and mAb A63 is consistent with known facts concerning telomerase protein synthesis 
and function. The telomerase catalytic subunit (TERT) is synthesized in the cytoplasm just 
like other proteins. Since its biological function occurs inside the nucleus, TERT requires 
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transportation into the nucleus after synthesis. This shuttling mechanism for the enzyme is 
well regulated by a sophisticated system involving a key signalling protein, 14-3-3 
(Seimiya et al. 2000). However, Western blotting experiments showed that the enzyme is 
found only in nuclear extracts but not cytoplasmic extracts. Based on the above 
information, the enzyme activity detected in cytoplasmic staining in immunohistology 
could be unreal, or due to the relatively small amounts of the enzyme present, or due to the 
fact that newly synthesized TERT in the cytoplasm is heterogeneous in size. Newly 
synthesized TERT in cytoplasm is presumably naked or incomplete，so that it can be bound 
by antibodies in normal buffer and its binding by antibodies could be easily lost when the 
Enhancing buffer is applied. 
Thus, it is not surprising that previous investigators encountered great difficulty in 
detecting telomerase histologically not only because of the low abundance of the enzyme 
in the cells, but also because it is well buried inside the nuclear scaffold. The solution found 
by these investigators was to use a signal amplification system marketed by Dako (Wada et 
al. 2000) or SykTek Labs (Logan, UT; Tahara et al. 1999). However, this approach did not 
specifically retrieve the TERT antigen from the nucleus like the Enhancing buffer, but 
instead, amplified the antigenic activity present in the cytoplasm only (Leung et al. 2005). 
6.2 Why hybridoma 476 failed to form ascites while hybridoma A63 
succeeded 
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The hybridoma technique invented in the 1970，s by Kohler and Milstein leads to the 
production of thousands of mouse hybridomas that produce various types of monoclonal 
antibodies. However, the majority of these monoclonal antibodies are raised against 
antigens belonging to animal species other than mouse, or that are microbial or plant in 
nature. That is, these antibodies are not autoreactive with respect to the mouse cell. Such 
antibodies are traditionally mass-produced in syngeneic mice as ascites, although 
bioreactors employing culture media only are also increasingly used. 
The general principle for producing antibodies as ascites is well understood. The mouse 
peritoneum is first primed with an adjuvant to create a cytokine-rich environment that 
favours the growth of the hybridoma cells as well as increasing the antibody-secreting 
activity of these cells (Hoogenraad et al. 1983; Kints et al. 1989; Jones et al. 1990). It was 
discovered that the number of resident cells in the peritoneum would drastically increase 
after adjuvant priming and most of these cells were polymophonuclear neutrophils (PMN). 
PMNs are capable of rapidly migrating to inflammatory sites and maintaining the 
inflammatory environment. Among the cytokines and chemokines secreted by the 
peritoneal resident cells, IL-6 was found to be especially dominant (Niu et al. 2008). Other 
cytokines and chemokines present such as LIX, KC，MIP-1, CXCL16 and PF-4, either 
attract or activate neutrophils, monocytes, dendritic cells or natural killer cells. IL-6 is 
known to be a growth factor for myeloma or plasma cells, and it also up-regulates Ig 
synthesis (Kishimoto et al. 1989; Hirano 1998). 
However, hybridoma 476 is unusual as it is unable to grow in the mouse peritoneum. The 
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reason for this is the fact that mAb 476 is a cross-reactive antibody that can recognize the 
TERT protein in human, mouse and fish (Figure 5.10, Figure 5.11, and Figure 5.12). The 
reactivity to mouse TERT makes it a true auto-antibody. It is believed that mAb 476 
produced inside the hybridoma can bind to the mouse TERT in the cytoplasm. This 
auto-reactivity exists to a certain level under normal culture conditions but this is not 
harmful to the survival of the cell. However, in the primed peritoneum when IL-6 is 
present abundantly, the antibody synthesis in the hybridoma 476 cells will increase 
dramatically, so that more antibodies will bind to the mouse TERT protein. 
The binding between mouse TERT proteins and mAb 476 antibodies inside the hybridoma 
cell forms immune-complexes. It is believed that these complexes induce apoptosis in the 
cells directly rather than the fact that the TERT protein when bound by antibodies loses 
telomerase activity which then triggers the apoptosis. Apoptosis appears to be caused by 
the transportation of the immune-complexes to the nucleus by the telomerase transport 
system, which leads to organelle stress (Niu et al. 2008). 
Hybridoma A63, unlike hybridoma 476，was able to grow in primed peritoneum and form 
ascites. The reason for this is likely to be the fact that mAb A63 is not able to react with 
mouse TERT although it recognizes TERT in human cells (Figure 5.10). Thus, the 
auto-reactivity problem of hybridoma 476 does not exist for hybridoma A63. Thus, 
although the IL-6 present in the peritoneum of the adjuvant-primed mice will increase the 
antibody synthesis in hybridoma A63 cells, this, however, will not trigger any apoptosis in 
these cells and consequently ascites will be formed. 
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6.3 Can IL-6 be used to treat autoimmune diseases? 
Auto-reactive B cells are found commonly in patients suffering from autoimmune diseases. 
These cells survive under certain conditions without being eliminated. The conventional 
treatment of B cell-related autoimmune diseases is to use anti-inflammatory drugs to limit 
the proliferative ability of these cells or their antibody synthesis. For example, 
glucocorticoid (GC) steroid hormones are often used that bind with the glucocorticoid 
receptor inside cells which thus trigger various intracellular signaling pathways that 
down-regulate the expression of genes encoding for the cytokines: IL-1, IL-2, IL-3，IL-4, 
IL-5，IL-6, IL-8 and IFN- Y • The most important are IL-2 and IL-6. IL-2 affects the 
activation of T cells and IL-6 mediates clone expansion and antibody synthesis of B cells 
(Leung and Bloom 2003). GC can also induce the synthesis of lipocortin (annexin-1), 
which is a very potent anti-inflammatory substance (Almawi et al. 1996). GC is commonly 
used in autoimmune disease treatment for a relatively long time, resulting in various side 
effects including systemic immunosuppression and hyperglycemia. 
A more recent approach in therapy works by direct neutralization of the pivotal cytokines 
involved in the pro-inflammatory immune responses using monoclonal antibodies. Tumor 
necrosis factor alpha (TNFa) is shown to play an important role in the development of 
rheumatoid arthritis (RA), an autoimmune disease involving abnormal B cell-T cell 
interaction. TNFa released from activated macrophages can further activate T cells, which 
then promote the clonal expansion of auto-reactive B cells. Thus, anti-TNFa monoclonal 
antibody can be used to neutralize the released TNFa and hence reduce the inflammatory 
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cell population, including auto-antibody producing B cell population (Elliott and Maini 
1995). The clonal expansion of auto-reactive B cells and their antibody-producing ability 
can also be up-regulated by IL-6, for example, in the pro-inflammatory environment in RA. 
However, this function can be blocked by inhibiting the binding between IL-6 and its 
cell-surface receptor on various cells including B cells. Thus, the use of monoclonal 
antibodies to the IL-6 receptor is an exciting new possibility for the therapy of rheumatoid 
arthritis (Nakahara and Nishimoto 2006). Under such conditions, the auto-reactive B cells' 
replicative ability or their ability to secrete antibodies are both inhibited, and the disease 
symptoms would then be weakened. Although therapy using monoclonal antibodies for 
autoimmune diseases is more specific than the use of systemic immunosuppressive drugs 
like glucocorticoids, there is still the immunosuppression side-effect because of the 
decrease in the antibody-producing ability of the whole body's immune system. 
In my study, however, I have described a paradox about the role of IL-6 function in the 
survival of auto-reactive B cells, which leads us to a new way of thinking about 
auto-immune disease therapy. As discussed in 6.2，the auto-reactive 476 B cells can 
survive in culture if no IL-6 was present. The antibodies produced in the cells would bind 
to telomerase synthesized in the cytoplasm and these would form immune-complexes 
inside the cell. Without IL-6, only small amounts of these immune-complexes would be 
formed. However, in the presence of IL-6, increased amounts of antibodies would be 
produced which would bind to more telomerase in the cytoplasm, and more 
immune-complexes would be formed. As a result, nuclear stress would ensue due to 
transportation of a heavy burden of these immune-complexes to the nucleus. Once the 
103 
auto-reactive B cells cannot tolerate this stress, they commit suicide (Niu et al. 2008). This 
finding is interesting because this suggests a hypothetical way of using a pro-inflammatory 
agent to cure an autoimmune disease. If IL-6 is shown to be able to kill auto-reactive B 
cells, it can then be used to treat patients suffering from certain autoimmune diseases. This 
treatment has the advantage over ones using broad anti-inflammatory agents because IL-6 
targets the specific auto-reactive B cells and not ones that are non-self reactive. This 
means the auto-reactive B cells can be specifically killed without affecting the normal 
immune defense mechanism. 
6.4 Possible use of monoclonal antibodies in cancer therapy 
Cancer immuno-therapy using monoclonal antibodies is a relatively new and developing 
method for cancer treatment. The central principle of using monoclonal antibody to treat 
cancer is the fact that some cancer cells express specific tumor antigens on the cell surface, 
which can be targetted by specific antibodies. A well-known antibody is called Herceptin, 
the first FDA-approved humanized anti-cancer antibody. It recognizes a tumor antigen 
called Her-2, which is expressed in 20-30% of early-stage breast cancer (Range et al. 2001). 
Another cancer treatment using monoclonal antibodies targetting tumor antigens expressed 
on the cell surface is specific for FasL (Mouawad et al. 2000). Such antibodies can bind to 
their target antigens directly. However, some tumor antigens are located inside the cells, 
either in the cytoplasm or the nucleus. Although antibodies can function intracellularly, 
they must be able enter the target cell from outside in the body fluid in the first place. An 
example of this is anti-RNP antibodies, which were shown to be able to penetrate human 
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mononulcear cells (Alarcon-Segovia et al. 1978); another is anti-listeria toxin antibodies, 
which were found to protect macrophages from the toxic effect of listeria (Edelson and 
Unanue 2001). It is possible that antibodies can be made to enter into cells by using carriers 
or retro-viruses, but these antibodies must be presented in the form of 
intracellular-expressed single chain Ig，e.g. recombinant adenovirus encoding an 
anti-erbB-2 single chain antibody (Deshane et al. 1995). Intracellular antibodies 
(intrabodies) can also be introduced to cells by using lipofection, in the form of gene 
transfection. Thus, DNA encoding the antibody single chain can be injected into the cell 
together with a synthetic cationic lipid, DOTMA (Feigner et al. 1987). Intrabodies thus 
expressed can function either by direct neutralization of the targeted protein or by 
preventing it from translocating to its normal destination. 
Telomerase is an example of a tumor antigen that is buried deeply inside the cell nuclear 
matrix and hence, is extremely difficult for antibodies to reach to (Figure 6.2). Thus, when 
using telomerase as the target, TERT in the cytoplasm should be used. Another possible 
way to destroy telomerase activity in the cell is to target the TERT mRNA using inhibitory 
anti-sense RNA (Bajpai et al. 2005). In addition, it is also possible to use TERT to train a 
patient's cytotoxic T lymphocytes (CTLs). As an overexpressed antigen in tumor cells, 
TERT fragments will be expressed on the cell surface of the tumor cells through MHC 
class I molecules, which is normally ignored by our immune system in non-autoreactive 
conditions. However, CTLs can be educated in vitro to recognize these self antigens and 
become activated. The activated T cells can be injected back into the patient's body to 
recognize the TERT fragments expressed through MHC class I molecules, which can then 
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induce apoptosis in the tumor cells. Another way is to use other antigen presenting cells 
(APCs) such as dendritic cells. Potent APCs can be trained or manipulated in vitro to 
present tumor antigens that are usually not expressed on the tumor cells surface, to T cells 
in an efficient manner. For example, the dendritomas formed by fusing mature dendritic 
cells with allogeneic human hepatocellular carcinoma cells can be used to activate 
autologous cytotoxic T lymphocytes (Chan et al. 2002). 
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6.5 Prospects on study 
I found the reason why mAb 476 and mAb A63 failed to bind to telomerase present in the 
nucleus ofHL-60 cells under normal immunostaining conditions. I conclude that the whole 
TERT antigen is normally buried deep inside the nucleus, making it difficult for the 
antibody to reach to. However, this conclusion is only drawn from the comparison between 
two monoclonal antibodies, mAb 476 and mAb A63. More investigations need to be 
performed using other monoclonal antibodies against antigenic epitopes located in 
different parts of the TERT antigen in future research. Furthermore, subtle differences 
were observed between mAb 476 and mAb A63 in the staining of telomerase in both the 
medaka fish and in tumor tissues, the reason for which needs to be determined. 
Previous studies showing the cytoplasmic staining in tumor cells of telomerase may be 
misleading, because they disagree with the fact that telomerase plays its biologic function 
in the nucleus rather than in the cytoplasm. Thus, these studies need to be repeated to 
improve the staining specificity by using new antigen retrieval techniques such as the use 
of the Enhancing buffer. Moreover, immuno-histochemical staining only provides partial 
evidence of telomerase activity, so that firm conclusions could only be drawn with the 
support of indirect evidences, e.g. from Western blotting experiments analysing fractions 
from different cell compartments, from in situ hybridization using RNA probes (against 
TERC as target), or from TRAP assays analysing different compartments of the cell. 
I also found the reason why hybridoma 476 failed to grow as ascites in the mouse 
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peritoneum while hybridoma A63 could successfully grow. This is due to the fact that mAb 
A63 does not bind to mouse telomerase and as such, A63 cells do not commit suicide. An 
interesting question that remains to be answered is: how many other types of auto-reactive 
hybridoma cells have the same suicide potential, or is this unique for auto-reactive 
N-TERT-antibody-producing hybridomas? 
Lastly, telomerase targeting by monoclonal antibodies may be used for medical purposes, 
especially in cancer treatment. This is because telomerase is up-regulated in cancer cells, 
which is significantly different from normal, non-proliferative somatic cells. This unique 
feature makes telomerase a good target for cancer treatment because normal tissues will 
not be harmed if telomerase-targeting therapy is applied. However, since telomerase is an 
intracellular antigen buried inside the nucleus, telomerase-targeting is difficult, so that 
using monoclonal antibodies to target the cytoplasmic telomerase may be preferred. Even 
here, it remains a challenge on how to introduce the antibodies into the cancer cells, 
including the requirement that, at the same time, these antibodies do not enter normal cells. 
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Figure 6.1 One possibility explaining why mAb 476 or mAb A63 cannot bind to TERT 
inside the nucleus under normal conditions, due to masking by accessory proteins 
belonging to the enzyme (A). In staining conditions using the Enhancing buffer, the 














Figure 6.2 Another possibility explaining why mAb 476 or mAb A63 cannot bind to 
TERT inside the nucleus under normal staining conditions, due to telomerase being buried 
deeply inside the nuclear matrix (A). In staining conditions using the Enhancing buffer, the 
nuclear matrix is opened allowing the antibody to reach the telomerase antigen inside the 
nucleus (B). NLS-Nucleolus. 
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